Dyes in aquaculture and reference points for action

European Food Safety Authority (EFSA),
André Penninks, Katleen Baert, Sara Levorato and Marco Binaglia

Abstract
The European Commission requested EFSA to evaluate whether a series of dyes are covered by the ‘Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action (RPAs) for non-allowed pharmacologically active substances present in food of animal origin’ and to which group they should be attributed according to this guidance. Although these substances are not registered for use in food-producing animals in the European Union, they may be used illegally in aquaculture for their antimicrobial properties. It was concluded that acriflavine, 3-aminoacridine, aminoacridine, basic blue 7, brilliant green, leucobrilliant green, C.I. basic blue 26, chloranil, crystal violet, leucocrystal violet, dichlone, ethyl violet, methylene blue, new methylene blue, Nile blue, pararosaniline base, proflavine, proflavine hydrochloride, rhodamine 6G and trypan red are covered by the guidance document and belong to group I. A toxicological screening value of 0.0025 μg/kg body weight per day is applicable. Azure blue and potassium permanganate were excluded from the evaluation due to their inorganic nature.

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

Keywords: dyes, aquaculture, reference point for action, RPA, toxicological screening value, TSV

Requestor: European Commission

Question number: EFSA-Q-2016-00396

Correspondence: contam@efsaa.europa.eu
Acknowledgements: EFSA wishes to thank Laurentius (Ron) Hoogenboom and Rolaf Van Leeuwen for reviewing this scientific output.

Amendment: An editorial correction was carried out that does not materially affect the contents or outcome of this scientific output. The title has been revised from 'Dyes used in aquaculture' to 'Dyes in aquaculture and reference points for action' to clarify the context in which this report should be considered. Furthermore, the illegal character of the use of these substances has been specified in the abstract and the wording “dyes used in aquaculture” has been replaced by “dyes” on page 9. To avoid confusion, the older version has been removed from the EFSA Journal, but is available on request, as is a version showing all the changes made.

Suggested citation: EFSA (European Food Safety Authority), Penninks A, Baert K, Levorato S and Binaglia M, 2017. Scientific report on the dyes in aquaculture and reference points for action. EFSA Journal 2017;15(7):4920, 43 pp. https://doi.org/10.2903/j.efsa.2017.4920

ISSN: 1831-4732

© 2017 European Food Safety Authority. EFSA Journal published by John Wiley and Sons Ltd on behalf of European Food Safety Authority.

This is an open access article under the terms of the Creative Commons Attribution-NoDerivs License, which permits use and distribution in any medium, provided the original work is properly cited and no modifications or adaptations are made.

The EFSA Journal is a publication of the European Food Safety Authority, an agency of the European Union.
Table of contents

Abstract ......................................................................................................................... 1
1. Introduction .............................................................................................................. 6
  1.1. Background and Terms of Reference as provided by the requestor ..................... 6
  1.2. Interpretation of the Terms of Reference ............................................................. 6
  1.3. Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action ......................................................... 7
2. Data and methodologies ............................................................................................ 8
  2.1. Data and methodology to evaluate whether the substances are excluded from the guidance document .............................................................................................................. 9
    2.1.1. Evaluation whether the substance is a high potency carcinogen ...................... 9
    2.1.2. Evaluation whether the substance causes allergy ............................................. 9
    2.1.3. Evaluation whether the substance causes blood dyscrasias ............................. 10
    2.2. Data and methodology to allocate TSVs to the substances that are not excluded from the guidance document ................................................................. 10
    2.2.1. Evaluation whether genotoxicity can be excluded and whether the TSV of 0.0025 μg/kg bw per day is sufficiently protective ...................................................... 10
    2.2.2. Evaluation whether the substance has intended pharmacological effects on the nervous system or reproductive system and/or is a corticoid ........................................ 11
3. Answers to the terms of reference ......................................................................... 11
  3.1. Acriflavine (CAS 65589-70-0) .......................................................................... 11
    3.1.1. Inclusion/exclusion from guidance document ................................................. 11
      3.1.1.1. Q1: Is acriflavine a high potency carcinogen? ........................................... 11
      3.1.1.2. Q2: Is acriflavine causing allergy? ......................................................... 11
      3.1.1.3. Q3: Is acriflavine causing blood dyscrasias? .......................................... 11
      3.1.1.4. Conclusion ......................................................................................... 11
    3.1.2. Toxicological screening value ........................................................................ 12
      3.1.2.1. Evaluation of genotoxicity .................................................................... 12
    3.2. 3-Aminoacridine (CAS 581-29-3) and aminoacridine (CAS 90-45-9) .......... 12
      3.2.1. Inclusion/exclusion from guidance document ............................................. 12
        3.2.1.1. Q1: Are 3-aminoacridine and aminoacridine high potency carcinogens? 12
        3.2.1.2. Q2: Are 3-aminoacridine and aminoacridine causing allergy? ........... 12
        3.2.1.3. Q3: Are 3-aminoacridine and aminoacridine causing blood dyscrasias? 13
        3.2.1.4. Conclusion ....................................................................................... 13
      3.2.2. Toxicological screening value ................................................................. 13
        3.2.2.1. Evaluation of genotoxicity .............................................................. 13
    3.3. Azure blue/ultramarine (CAS 57455-37-5) ...................................................... 13
      3.3.1. Inclusion/exclusion from guidance document ............................................. 14
        3.3.1.1. Q1: Is basic blue 7 a high potency carcinogen? .................................. 14
        3.3.1.2. Q2: Is basic blue 7 causing allergy? ..................................................... 15
        3.3.1.3. Q3: Is basic blue 7 causing blood dyscrasias? .................................... 15
        3.3.1.4. Conclusion ....................................................................................... 15
      3.3.2. Toxicological screening value ................................................................. 15
        3.3.2.1. Evaluation of genotoxicity .............................................................. 15
    3.4. Basic blue 7/victoria pure blue BO (CAS 2390-60-5) ................................ 14
      3.4.1. Inclusion/exclusion from guidance document ............................................. 14
        3.4.1.1. Q1: Is basic blue 7 a high potency carcinogen? ................................. 14
        3.4.1.2. Q2: Is basic blue 7 causing allergy? ..................................................... 15
        3.4.1.3. Q3: Is basic blue 7 causing blood dyscrasias? .................................... 15
        3.4.1.4. Conclusion ....................................................................................... 15
      3.4.2. Toxicological screening value ................................................................. 15
        3.4.2.1. Evaluation of genotoxicity .............................................................. 15
    3.5. Brilliant green/C.I. basic green 1 (CAS 633-03-4) and leucobrilliant green (CAS 82-90-6) ................................................................. 16
      3.5.1. Inclusion/exclusion from guidance document ............................................. 16
        3.5.1.1. Q1: Are brilliant green and leucobrilliant green high potency carcinogens? 16
        3.5.1.2. Q2: Are brilliant green and leucobrilliant green causing allergy? ....... 17
        3.5.1.3. Q3: Are brilliant green and leucobrilliant green causing blood dyscrasias? 17
        3.5.1.4. Conclusion ....................................................................................... 17
      3.5.2. Toxicological screening value ................................................................. 17
        3.5.2.1. Evaluation of genotoxicity .............................................................. 17
    3.6. Basic blue 26 (CAS 2580-56-5) ................................................................. 18
      3.6.1. Inclusion/exclusion from guidance document ............................................. 18
        3.6.1.1. Q1: Is basic blue 26 a high potency carcinogen? ................................ 18
        3.6.1.2. Q2: Is basic blue 26 causing allergy? ..................................................... 18
        3.6.1.3. Q3: Is basic blue 26 causing blood dyscrasias? .................................... 18
        3.6.1.4. Conclusion ....................................................................................... 18
www.efs.europa.eu/efsajournal 3 EFSA Journal 2017;15(7):4920
3.6.2. Toxicological screening value
3.6.2.1. Evaluation of genotoxicity
3.7. Chloranil (CAS 118-75-2)
3.7.1. Inclusion/exclusion from guidance document
3.7.1.1. Q1: Is chloranil a high potency carcinogen?
3.7.1.2. Q2: Is chloranil causing allergy?
3.7.1.3. Q3: Is chloranil causing blood dyscrasias?
3.7.1.4. Conclusion
3.7.2. Toxicological screening value
3.7.2.1. Evaluation of genotoxicity
3.8. Crystal violet/gentian violet (CAS 548-62-9) and leucocrystal violet/leucogentian violet (CAS 603-48-5)
3.8.1. Inclusion/exclusion from guidance document
3.8.1.1. Q1: Are crystal violet and leucocrystal violet high potency carcinogens?
3.8.1.2. Q2: Are crystal violet and leucocrystal violet causing allergy?
3.8.1.3. Q3: Are crystal violet and leucocrystal violet causing blood dyscrasias?
3.8.1.4. Conclusion
3.8.2. Toxicological screening value
3.8.2.1. Evaluation of genotoxicity
3.9. Dichlone (CAS 117-80-6)
3.9.1. Inclusion/exclusion from guidance document
3.9.1.1. Q1: Is dichlone a high potency carcinogen?
3.9.1.2. Q2: Is dichlone causing allergy?
3.9.1.3. Q3: Is dichlone causing blood dyscrasias?
3.9.1.4. Conclusion
3.9.2. Toxicological screening value
3.9.2.1. Evaluation of genotoxicity
3.10. Ethyl violet (CAS 25279-06-3)
3.10.1. Inclusion/exclusion from guidance document
3.10.1.1. Q1: Is ethyl violet a high potency carcinogen?
3.10.1.2. Q2: Is ethyl violet causing allergy?
3.10.1.3. Q3: Is ethyl violet causing blood dyscrasias?
3.10.1.4. Conclusion
3.10.2. Toxicological screening value
3.10.2.1. Evaluation of genotoxicity
3.11. Methylene blue (CAS 61-73-4)
3.11.1. Inclusion/exclusion from guidance document
3.11.1.1. Q1: Is methylene blue a high potency carcinogen?
3.11.1.2. Q2: Is methylene blue causing allergy?
3.11.1.3. Q3: Is methylene blue causing blood dyscrasias?
3.11.1.4. Conclusion
3.11.2. Toxicological screening value
3.11.2.1. Evaluation of genotoxicity
3.12. New methylene blue/victoria blue R (CAS 2185-86-6)
3.12.1. Inclusion/exclusion from guidance document
3.12.1.1. Q1: Is victoria blue R a high potency carcinogen?
3.12.1.2. Q2: Is victoria blue R causing allergy?
3.12.1.3. Q3: Is victoria blue R causing blood dyscrasias?
3.12.1.4. Conclusion
3.12.2. Toxicological screening value
3.12.2.1. Evaluation of genotoxicity
3.13. Nile blue (CAS 2381-85-3)
3.13.1. Inclusion/exclusion from guidance document
3.13.1.1. Q1: Is Nile blue a high potency carcinogen?
3.13.1.2. Q2: Is Nile blue causing allergy?
3.13.1.3. Q3: Is Nile blue causing blood dyscrasias?
3.13.1.4. Conclusion
3.13.2. Toxicological screening value
3.14. Pararosaniline base (CAS 25620-78-4)
3.14.1. Inclusion/exclusion from guidance document
3.14.1.1. Q1: Is pararosaniline base a high potency carcinogen?
3.14.1.2. Q2: Is pararosaniline base causing allergy?
Dyes in aquaculture and reference points for action

3.14.1.3. Q3: Is pararosaniline base causing blood dyscrasias? ................................................................. 29
3.14.1.4. Conclusion ................................................................................................................................. 29
3.14.2. Toxicological screening value ........................................................................................................ 29
3.14.2.1. Evaluation of genotoxicity ........................................................................................................... 29
3.15. Potassium permanganate (CAS 7722-64-7) .......................................................................................... 30
3.15.1. Inclusion/exclusion from guidance document .................................................................................. 30
3.16. Proflavine (CAS 92-62-6) and proflavine hydrochloride (CAS 952-23-8) ............................................. 30
3.16.1. Inclusion/exclusion from guidance document .................................................................................. 30
3.16.1.1. Q1: Are proflavine and proflavine hydrochloride high potency carcinogens? ............................ 30
3.16.1.2. Q2: Are proflavine and proflavine hydrochloride causing allergy? .............................................. 31
3.16.1.3. Q3: Are proflavine and proflavine hydrochloride causing blood dyscrasias? ............................... 31
3.16.1.4. Conclusion ................................................................................................................................. 31
3.16.2. Toxicological screening value ........................................................................................................ 31
3.16.2.1. Evaluation of genotoxicity ........................................................................................................... 31
3.17. Rhodamine 6G (CAS 989-38-8) ........................................................................................................ 32
3.17.1. Inclusion/exclusion from guidance document .................................................................................. 32
3.17.1.1. Q1: Is rhodamine 6G a high potency carcinogen? ......................................................................... 32
3.17.1.2. Q2: Is rhodamine 6G causing allergy? .......................................................................................... 32
3.17.1.3. Q3: Is rhodamine 6G causing blood dyscrasias? ............................................................................ 32
3.17.1.4. Conclusion ................................................................................................................................. 32
3.17.2. Toxicological screening value ........................................................................................................ 32
3.17.2.1. Evaluation of genotoxicity ........................................................................................................... 32
3.18. Trypan red (CAS 574-64-1) ............................................................................................................... 33
3.18.1. Inclusion/exclusion from guidance document .................................................................................. 33
3.18.1.1. Q1: Is trypan red a high potency carcinogen? .............................................................................. 33
3.18.1.2. Q2: Is trypan red causing allergy? ............................................................................................... 34
3.18.1.3. Q3: Is trypan red causing blood dyscrasias? ................................................................................. 34
3.18.1.4. Conclusion ................................................................................................................................. 34
3.18.2. Toxicological screening value ........................................................................................................ 34
3.18.2.1. Evaluation of genotoxicity ........................................................................................................... 34
3.19. Summary (Table 2) ....................................................................................................................... 34
4. Conclusions ........................................................................................................................................ 35
References ............................................................................................................................................... 35
Abbreviations ............................................................................................................................................ 40
Appendix A – Literature search ............................................................................................................. 42
1. Introduction

1.1. Background and Terms of Reference as provided by the requestor

BACKGROUND

The EFSA CONTAM panel has adopted a scientific opinion entitled Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action (RPAs) for non-allowed pharmaceutically active substances present in food of animal origin.

In relation to the setting of reference points for action, the EFSA CONTAM Panel has subsequently delivered specific opinions related to the presence of chloramphenicol, nitrofurans, and malachite green and its metabolite leucomalachite green.

The already available opinions are used as a basis for discussions with Member States on an implementing act establishing reference points for action for non-allowed pharmaceutically active substances present in food of animal origin.

TERMS OF REFERENCE

In the context of Article 31 of Regulation (EC) No 178/2002, the Commission requests EFSA’s scientific and technical assistance on whether the dyes listed in Table 1 are covered by the above mentioned guidance document and, if so, to which group they should be attributed, or whether a specific scientific opinion would be needed.

Table 1: List of dyes covered by this Scientific report

| Name                        | CAS number   |
|-----------------------------|--------------|
| Acriflavine                 | 65589-70-0   |
| 3-Aminoacridine             | 581-29-3     |
| Aminoacridine               | 90-45-9      |
| Azure blue/ultramarine      | 57455-37-5   |
| Basic blue 7/victoria pure blue BO | 2390-60-5 |
| Brilliant green/C.I. basic green 1 | 633-03-4 |
| Leucobrilliant green        | 82-90-6      |
| C.I. basic blue 26          | 2580-56-5    |
| Chloranil                   | 118-75-2     |
| Crystal violet/gentian violet| 548-62-9     |
| Leucocrystal violet/leucogentian violet | 603-48-5 |
| Dichlorone                  | 117-80-6     |
| Ethyl violet                | 25275-06-3   |
| Methylene blue              | 61-73-4      |
| New methylene blue/victoria blue R | 2185-86-6 |
| Nile blue                   | 2381-85-3    |
| Pararosaniline base         | 25620-78-4   |
| Potassium permanganate      | 7722-64-7    |
| Proflavine                  | 92-62-6      |
| Proflavine hydrochloride    | 952-23-8     |
| Rhodamine 6G                | 989-38-8     |
| Trypan red                  | 574-64-1     |

1.2. Interpretation of the Terms of Reference

The European Food Safety Authority (EFSA) concluded that this Scientific Report should comprise:

a) the evaluation whether the substances listed in Table 1 are excluded from the Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action (RPAs) for non-allowed pharmaceutically active substances present in food of animal origin (EFSA CONTAM Panel, 2013);

b) the allocation of the substances that follow the above mentioned guidance document to the different groups of substances as defined in the guidance document.
1.3. Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action

According to Article 3 of Regulation (EC) No 470/2009 of the European Parliament and of the Council, any pharmacologically active substance intended for use in the Union in veterinary medicinal products (VMPs), which are to be administered to food-producing animals, shall be subject to an opinion of the European Medicines Agency (EMA) on the maximum residue limit (MRL), formulated by the Committee for Veterinary Medicinal Products (CVMP). Pharmacologically active substances, for which the EMA opinion concludes that no MRL is needed or that a (provisional) MRL should be established, are subsequently classified in Table 1 ‘allowed substances’ of Regulation (EU) 37/2010. Use of other pharmacologically active substances in VMPs is not allowed.

According to Article 18 of Regulation (EC) No 470/2009 stipulates that, for substances which are not classified as ‘allowed substances’ in accordance with that Regulation, a RPA may be established in order to ensure the functioning of controls for food of animal origin. Food of animal origin containing residues of such substances at or above the RPA is considered not to comply with Union legislation.

The EFSA Scientific Opinion entitled ‘Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action (RPAs) for non-allowed pharmacologically active substances present in food of animal origin’ (EFSA CONTAM Panel, 2013) identified a step-wise approach for establishing RPAs for various categories of non-allowed pharmacologically active substances. This Scientific Opinion is further referred in this Scientific Report to as ‘guidance document’. In this approach, a toxicological screening value (TSV) is assigned to the substance under evaluation, following the use of a decision tree (Figure 1). A TSV of 0.0025 µg/kg body weight (bw) per day is assigned to non-allowed pharmacologically active substances for which there is direct evidence of genotoxicity, for which there is an alert for genotoxicity (from structural activity relationships or read across), or for which there is lack of information on genotoxicity. The substances that belong to this category are referred to as Group I substances.

---

1 In this Scientific Report, where reference is made to European legislation (regulations, directives, decisions), the reference should be understood as relating to the most current amendment, unless otherwise stated.

2 Regulation (EC) No 470/2009 of the European Parliament and of the Council of 6 May 2009, laying down Community procedures for the establishment of residue limits of pharmacologically active substances in foodstuffs of animal origin, repealing Council Regulation (EEC) No 2377/90 and amending Directive 2001/82/EC of the European Parliament and of the Council and Regulation (EC) No 726/2004 of the European Parliament and of the Council Text with EEA relevance. OJ L 152, 16.6.2009, p. 1-22.

3 Commission Regulation (EU) No 37/2010 of 22 December 2009 on pharmacologically active substances and their classification regarding maximum residue limits in foodstuffs of animal origin. OJ L 15, 20.1.2010, p. 1-72.
Substances with intended pharmacological effects on the nervous system or the reproductive system, or that are corticoids, are referred to as Group II substances and a TSV of 0.0042 \( \mu g/kg \) bw per day is applied for this group.\(^4\)

For the remaining classes of non-allowed pharmacologically active substances, referred to as Group III substances, a TSV of 0.65 \( \mu g/kg \) bw per day is applied.

The assigned TSV is then used to calculate a Toxicologically Based Limit of Quantification (TBLOQ), which is compared with the Reasonably Achievable Lowest Limit of Quantification (RALLOQ) using a decision tree to establish an appropriate RPA (EFSA CONTAM Panel, 2013).

However, it should be noted that the CONTAM Panel identified circumstances where the European Commission might consider it appropriate to conduct a substance-specific risk assessment. These might include (i) where application of the proposed methodology results in a TBLOQ that is lower than the RALLOQ and there is little or no possibility of significant improvement in the analytical capability within a short to medium time frame, (ii) substances causing blood dyscrasias (such as aplastic anaemia) or allergy, or that are high potency carcinogens,\(^5\) which are outside the scope of this guidance document or (iii) where there is experimental or other evidence that the use of the TSV of 0.0025 \( \mu g/kg \) bw per day for Group I may not be adequately health protective.\(^6\) Further details regarding the interpretation of these circumstances is given under Sections 2.1.2 and 2.2.1 of this Scientific Report.

### 2. Data and methodologies

The guidance document (EFSA CONTAM Panel, 2013) provides a simple and pragmatic approach to establish RPAs for non-allowed pharmacologically active substances present in food of animal origin. Following this approach, EFSA applied a screening methodology to search for information that allows answering the terms of reference. Further details are given below.

---

\(^4\) The guidance document specifies that Group II substances are substances that are acting (or intend to act) pharmacologically on the nervous or reproductive system, or being a corticoid. The CONTAM Panel agreed at its 83rd meeting that only the intended use should be considered to allocate substances to Group II. http://www.efsa.europa.eu/sites/default/files/event/170314-m.pdf

\(^5\) i.e. aflatoxin-like, azoxy- or N-nitroso-compounds, benzidines, hydrazines) (EFSA Scientific Committee, 2012).

---

Figure 1: Decision tree for assigning toxicological screening values (TSVs) for non-allowed pharmacologically active substances (based on EFSA CONTAM Panel, 2013)
Information regarding the identity of the substances, i.e. IUPAC name, EC number, chemical formula, smiles code and chemical structure was retrieved using Pubchem 6 and the ECHA website. 7

2.1. Data and methodology to evaluate whether the substances are excluded from the guidance document

The following evaluations were carried out to evaluate whether the above mentioned guidance document (EFSA CONTAM Panel, 2013) is applicable to the substances listed in Table 1:

- evaluation whether the substance is a high potency carcinogen,
- evaluation whether the substance causes allergy,
- evaluation whether the substance causes blood dyscrasias.

2.1.1. Evaluation whether the substance is a high potency carcinogen

According to the EFSA Scientific Committee (2012), aflatoxin-like compounds, azoxy- or N-nitroso-compounds, benzidines and hydrazines are considered to be high potency carcinogens. Based on the chemical structure of the substance, it was determined whether the substance should be considered to be a high potency carcinogen.

2.1.2. Evaluation whether the substance causes allergy

As described in Section 1.3, a substance-specific risk assessment is required for non-allowed pharmacologically active substances that cause 'Allergy'. 'Allergy' can refer to substances that can cause food- or respiratory allergy (both Type I, immediate type hypersensitivity reactions, immunoglobulin E (IgE)-mediated) or can cause skin allergy (Type IV, delayed type hypersensitivity, T-cell-mediated hypersensitivity: ACD, allergic contact dermatitis).

Sometimes, systemic reactivation of ACD or systemic contact dermatitis (SCD) can occur when individuals with a contact allergy to a certain skin allergen are exposed systemically to the same allergen via exposure routes other than by cutaneous contact, like orally or by injection. In these situations, the systemically administered allergen may reach the skin through the circulatory system. However, only relatively few patients have been documented in literature as having had a significant contribution to their skin allergic state by allergen exposure through routes of exposure other than by cutaneous contact. SCD due to oral re-exposure has mainly been described (Lampel and Silvestri, 2014) for some antibiotics (e.g. neomycin and closely related antibiotics) and several metals (e.g. nickel, cobalt, chromium). A relatively high dose of the contact allergen is usually needed. From the results of a study by Jensen et al. (2006), it was shown that in case of oral nickel exposure about 1% of nickel-sensitive patients may react systemically to every day nickel exposure (0.22–0.35 mg Ni) and 10% may react to a diet composed of foods rich in nickel (0.55–1.33 mg Ni).

For certain dyes, skin sensitisation resulting in ACD can only be induced upon cutaneous contact. In individuals suffering already from contact allergy to a dye, reactivation of ACD will only occur upon renewed cutaneous contact, whereas after oral exposure to the dye present in food no reactivation of ACD or SCD has been reported in literature. Therefore, skin sensitisation by dyes is to be disregarded as exclusion criterion for establishment of RPAs for dyes when taking into account the irrelevance of the oral route of exposure in individuals already sensitised to certain dyes.

Overall, it is concluded that under the intended conditions for use of dyes in aquaculture, there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to the dye. The CONTAM Panel agreed with this conclusion at its 83rd plenary meeting. 8

A stepwise approach was followed to collect information to evaluate whether the dyes cause allergy. First it was checked whether the dye had been evaluated by the European Chemicals Agency (ECHA), the EMA, the Joint FAO/WHO Expert Committee on Food Additives (JECFA) or one of the Scientific Committees advising the European Commission in relation to consumer safety, health and the environment. Also the following text books and databases were consulted to collect information regarding the potential of the substance to cause allergy.

6 https://pubchem.ncbi.nlm.nih.gov/
7 https://www.echa.europa.eu/
8 http://www.efsa.europa.eu/sites/default/files/event/170314-m.pdf
Rietschel RL and Fowler JF, 2008. Fisher’s contact dermatitis 6. BC Decker Inc, Hamilton, 862 p.
Plakas SM, Doerge DR and Turnipseed SB, 1999. Disposition and metabolism of malachite green and other therapeutic dyes in fish. In Smith DJ, Gingerich WH, Beconi-Barker MG (Eds). Xenobiotics in fish. Springer, New York, 149–166.
Andersen KE and Maibach HI, 1983. Drugs used topically. In: de Weck AL and Bundgaard H (Eds), 1983. Allergic reactions to drugs. Springer-Verlag, Berlin, 313–377.
Martindale: The complete Drug Reference.9

In case no information was identified in the first step, scientific literature searches (Appendix A) were conducted and the outcome from computational toxicology was considered. For the latter, the following information sources were consulted:

- Alerts reported on the ECHA website7
- QSAR toolbox 3.3.5.1710
- Danish QSAR database.11

2.1.3. Evaluation whether the substance causes blood dyscrasias

A stepwise approach was followed to collect information for this evaluation.

First, it was checked whether the dyes had been evaluated by ECHA, EMA, JECFA or one of the Scientific Committees advising the European Commission in relation to consumer safety, health and the environment. Also, Martindale9 was consulted to collect information regarding the potential of the substance to cause blood dyscrasias.

Secondly, a literature search was conducted (Appendix A) and the papers were retrieved for the relevant studies.

2.2. Data and methodology to allocate TSVs to the substances that are not excluded from the guidance document

2.2.1. Evaluation whether the substance should be regarded as genotoxic and whether the TSV of 0.0025 μg/kg bw per day is sufficiently protective

It was checked whether the dyes had been evaluated by ECHA, EMA, JECFA or one of the Scientific Committees advising the European Commission in relation to consumer safety, health and the environment. The available information was used in the evaluation.

In addition, a literature search was conducted to identify scientific papers in the open literature. Title and abstracts were screened to identify information to reply to this question. No evaluation of the full papers nor the quality of the study was conducted. The search strings are reported in Appendix A.

For the substances for which no or limited data were identified from the scientific literature and previous assessments, the outcome from computational toxicology was considered by consulting the following information sources:

- Alerts reported on the ECHA website7
- QSAR toolbox 3.3.5.1710
- Danish QSAR database.11

Since no evaluation of the quality of the identified information is conducted in the applied methodology, the classification of the substance regarding the genotoxicity based on the identified information from the literature and in silico methods should not be considered as conclusive. EFSA evaluated whether under the applied guidance document, the substance could be regarded as non-genotoxic and consequently be removed from group I. However, only a full evaluation of the available information, either by a previous assessment or (an) expert(s) in the area, would allow allocation of the substance to group II and III.

The CONTAM Panel noted at its 83rd plenary meeting8 that high potency carcinogens are excluded from the guidance document and that the guidance document presents a simple and pragmatic approach for establishing RPAs. Therefore, the CONTAM Panel agreed that no specific evaluation of the

---

9 https://www.medicinescomplete.com/mc/martindale/current/login.htm?uri=https%3A%2F%2Fwww.medicinescomplete.com%2Fmc%2Fmartindale%2F2009%2F
10 http://www.oecd.org/chemicalsafety/risk-assessment/theoecdgqsartoolbox.htm
11 http://qsar.food.dtu.dk/
2.2.2. Evaluation whether the substance has intended pharmacological effects on the nervous system or reproductive system and/or is a corticoid

The dyes evaluated in this Scientific Report are in principle used for antimicrobial purposes and not to act on the nervous or reproductive system and/or as a corticosteroid. Substances for which genotoxicity can be excluded are therefore classified in group III.

3. Answers to the terms of reference

3.1. Acriflavine (CAS 65589-70-0)

IUPAC name: acridine-3,6-diamine;10-methylacridin-10-ium-3,6-diamine;chloride
EC number: 617-132-5
Molecular formula: C_{27}H_{25}N_{6}.Cl
Smiles code:
C[N+1]=C=CC(C=CC2=CC3=CC(C=CC3=N)N.C1=CC=CC2=NC3=C(C=CC(C=CC3)N)C=C21)N.[Cl-]

3.1.1. Inclusion/exclusion from the guidance document

3.1.1.1. Q1: Is acriflavine a high potency carcinogen?

Acriflavine (Figure 2) does not belong to the chemical classes defined as high potency carcinogens.

3.1.1.2. Q2: Is acriflavine causing allergy?

In several case reports, it has been described that upon occupational exposure, acriflavine can cause ACD (Plakas et al., 1999; Rietschel and Fowler, 2008), and was reported in a fishery worker after repeated application of acriflavine as an antiparasitic agent in aquarium fish (Goh, 1986). As no food or respiratory allergy was identified in the literature search for acriflavine, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of acriflavine.

3.1.1.3. Q3: Is acriflavine causing blood dyscrasias?

No studies regarding blood dyscrasias caused by acriflavine were identified in the literature search.

3.1.1.4. Conclusion

Based on the chemical structure of acriflavine and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for acriflavine.
3.1.2. Toxicological screening value

3.1.2.1. Evaluation of genotoxicity

Several studies reported that acriflavine can induce mutations in different type of microorganisms (i.e. bacteria, yeast, moulds) (Witkin, 1947; Demerec et al., 1951; Marcovich, 1951; Arlett, 1957; Mejsel and Sokolova, 1960; Faulkner and Arlett, 1964; Monita and Mifuchi, 1965; Ball and Roper, 1966; Kot et al., 1975; Younis et al., 1975; Ali et al., 1978; Rosato and De Azevedo, 1978; Aoki et al., 2005). Acriflavine was also found to inhibit DNA-repair following UV-induced damage in bacteria (Doudney et al., 1964; Likhacheva, 1970; Setlow and Boling, 1970; Harm, 1973) and in human cells (Ben-Hur and Ben-Ishai, 1971; Kleijer et al., 1973).

The mutagenic potential of acriflavine was also reported in algae (Singh and Dikshit, 1976; Dorthu et al., 1992) and Drosophila melanogaster (Mitchell et al., 1981; Alba et al., 1983; Xamena et al., 1984).

Acriflavine exposure caused DNA damages in both cultured human lymphocytes and lung cancer cells (NCI-H460), as evaluated by the comet assay (Obstoy et al., 2015). Sudharsan Raj and Heddle (1980) reported increased frequencies of micronuclei and sister chromatid exchanges in Chinese hamster ovary cells exposed in vitro to acriflavine.

An in vivo study reported that acriflavine can induce chromosome alterations in C3H mice (Schleiermacher, 1967).

Based on this information, EFSA concluded that under the applied approach, acriflavine should be regarded as genotoxic. This substance consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.2. 3-Aminoacridine (CAS 581-29-3) and aminoacridine (CAS 90-45-9)

3-Aminoacridine
IUPAC name: acridin-3-amine
EC number: 209-461-4
Molecular formula: C_{13}H_{10}N_{2}
Smiles code: C1=CC=C2C=C3C=CC=CC3=N2N

Aminoacridine
IUPAC name: acridin-9-amine
EC number: 201-995-6
Molecular formula: C_{13}H_{10}N_{2}
Smiles code: C1=CC=C2C=C3C=CC3=N2N

3.2.1. Inclusion/exclusion from the guidance document

3.2.1.1. Q1: Are 3-aminoacridine and aminoacridine high potency carcinogens?

3-Aminoacridine and aminoacridine (Figure 3) do not belong to the chemical classes defined as high potency carcinogens.

Figure 3: Chemical structure of 3-aminoacridine (left) and aminoacridine (right)
3.2.1.2. **Q2: Are 3-aminoacridine and aminoacridine causing allergy?**

As indicated on the ECHA website, 3-aminoacridine and aminoacridine are suspected skin sensitisers as predicted with moderate reliability with the CAESAR skin sensitisation model in the VEGA (Q)SAR platform.\(^{12,13}\)

As no food or respiratory allergy was identified in the literature search for 3-aminoacridine and aminoacridine, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of 3-aminoacridine and aminoacridine.

3.2.1.3. **Q3: Are 3-aminoacridine and aminoacridine causing blood dyscrasias?**

No studies regarding blood dyscrasias were identified in the literature search.

3.2.1.4. **Conclusion**

Based on the chemical structures of 3-aminoacridine and aminoacridine and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for 3-aminoacridine and aminoacridine.

3.2.2. **Toxicological screening value**

3.2.2.1. **Evaluation of genotoxicity**

3-Aminoacridine exerted mutagenic activity in bacteria (Brown et al., 1980; Ferguson and MacPhee, 1983) and plants (D’Amato, 1952), whereas Ferguson (1984) reported that it was ineffective in producing respiratory-deficient mutants in Saccharomyces cerevisiae. No other relevant information on the genotoxicity of 3-aminoacridine was retrieved from the literature search.

Many studies have demonstrated that aminoacridine is mutagenic in bacteria (Deluca et al., 1977; Webb et al., 1979; Firth et al., 1981; Young et al., 1981; Ferguson and MacPhee, 1983; Ferguson et al., 1983; MacPhee et al., 1983; Pons and Mueller, 1990; Hoffman et al., 1996; Acharya et al., 2007). In the study conducted by Calendi et al. (1974), aminoacridine was not mutagenic in Escherichia coli, whereas it induced chromosomal aberrations in Allium cepa root tips and human leukocytes.

Aminoacridine induced sister chromatid exchange in Chinese hamster lung and ovary cells (Baker et al., 1983) and DNA damage in human lymphoblastoid cells in the comet assay (Henderson et al., 1998). On the other hand, Deluca et al. (1977) reported no detectable mutagenicity in human lymphoblast at the hprt locus.

In the unscheduled DNA synthesis test, positive results were reported by Benigni et al. (1990) in human fibroblast, whereas no increase was detected in testicular cells isolated from male mice in vitro (Beikirch, 1977) and in HeLa cells (Martin et al., 1978).

Matsuda et al. (2016) found that aminoacridine has inhibitory effects on the DNA-damage response in human cells; the authors suggested that this could be responsible for the chromosome-damaging potential of the compound.

Based on this information, EFSA concluded that under the applied approach, aminoacridine and 3-aminoacridine, should be regarded as genotoxic. Both substances consequently belong to Group I as defined in the guidance document and a TSV of 0.0025 µg/kg bw per day should be used in case an RPA were to be established.

3.3. **Azure blue/ultramarine (CAS 57455-37-5)**

- IUPAC name: -
- EC number: 611-533-9
- Molecular formula: Al₆Na₈O₂₄S₃Si₆
- Smiles code: \([\text{O-}][\text{Si}][\text{O-}][\text{O-}][\text{O-}][\text{O-}][\text{O-}][\text{Na}^+]\]

---

\(^{12}\) https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.001.814

\(^{13}\) https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.008.603
3.3.1. Inclusion/exclusion from the guidance document

As shown in Figure 4, azure blue is a mixture of different inorganic compounds, of which thiozonide $\text{S}_3^-$ has an intense blue colour. The other compounds are not known as dyes or as pharmacologically active substances. EFSA noted that besides thiozonide, azure blue contains sodium aluminium silicate which is used as an anticaking agent in foods (E 554).

The CONTAM Panel agreed at the 83rd Panel meeting that inorganic substances should be excluded from the guidance document (see Section 2.2.1). Therefore, the guidance document cannot be applied to azure blue and no TSV can be assigned to this compound.

3.4. Basic blue 7/victoria pure blue BO (CAS 2390-60-5)

IUPAC name: [4-[bis[4-(diethylamino)phenyl]methylidene]naphthalen-1-ylidene]-ethylazanium; chloride

EC number: 219-232-0

Molecular formula: $\text{C}_{33}\text{H}_{40}\text{ClN}_3$

Smiles code: \text{CC(NH$^+$)=C1=C(C2=CC=C(C=C2)N(CC)CC)C3=CC=C(C=C3)N(CC)CC)C4=CC=CC=CC14.[Cl-]}

3.4.1. Inclusion/exclusion from the guidance document

3.4.1. Q1: Is basic blue 7 a high potency carcinogen?

Basic blue 7 (Figure 5) does not belong to the chemical classes defined as high potency carcinogens.
3.4.1.2. Q2: Is basic blue 7 causing allergy?

In 2000, the Scientific Committee on Cosmetic Products and Non-Food Products intended for consumers (SCCNFP) evaluated basic blue 7 as a hair tinting product and concluded that 'on the basis of the data provided, it cannot be excluded that this substance is a contact allergen. Cosmetic products containing this substance shall carry a label warning of a risk of sensitisation'.

As no food or respiratory allergy was identified in the literature search for basic blue 7, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of basic blue 7.

3.4.1.3. Q3: Is basic blue 7 causing blood dyscrasias?

No studies regarding blood dyscrasias caused by basic blue 7 were identified in the literature search.

3.4.1.4. Conclusion

Based on the chemical structure of basic blue 7 and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for basic blue 7.

3.4.2. Toxicological screening value

3.4.2.1. Evaluation of genotoxicity

Basic blue 7 was found to efficiently bind to DNA and to mediate its photochemical destruction in tumour cells (Lewis and Indig, 2001, 2002). No other relevant information was identified in the literature search.

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, basic blue 7 is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts with moderate reliability that basic blue 7 is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for in vitro mutagenicity (Ames), 'in vivo mutagenicity (micronucleus)' and structural

---

**Figure 5:** Chemical structure of basic blue 7

3.4.1.2. Q2: Is basic blue 7 causing allergy?

In 2000, the Scientific Committee on Cosmetic Products and Non-Food Products intended for consumers (SCCNFP) evaluated basic blue 7 as a hair tinting product and concluded that 'on the basis of the data provided, it cannot be excluded that this substance is a contact allergen. Cosmetic products containing this substance shall carry a label warning of a risk of sensitisation'.

As no food or respiratory allergy was identified in the literature search for basic blue 7, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of basic blue 7.

3.4.1.3. Q3: Is basic blue 7 causing blood dyscrasias?

No studies regarding blood dyscrasias caused by basic blue 7 were identified in the literature search.

3.4.1.4. Conclusion

Based on the chemical structure of basic blue 7 and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for basic blue 7.

3.4.2. Toxicological screening value

3.4.2.1. Evaluation of genotoxicity

Basic blue 7 was found to efficiently bind to DNA and to mediate its photochemical destruction in tumour cells (Lewis and Indig, 2001, 2002). No other relevant information was identified in the literature search.

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, basic blue 7 is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts with moderate reliability that basic blue 7 is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for in vitro mutagenicity (Ames), 'in vivo mutagenicity (micronucleus)' and structural

---

14 http://ec.europa.eu/health/scientific_committees/consumer_safety/opinions/sccnfp_opinions_97_04/sccp_out118_en.htm
15 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.017.485
16 EFSA noted that micronuclei are due to clastogenic effects.
alerts for genotoxic carcinogenicity by ISS. Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, Ames test in Salmonella Typhimurium (in vitro), Syrian hamster embryo cell transformation, sex-linked recessive lethal test in Drosophila and sister chromatid exchange in mouse bone marrow cells (only predictions inside the applicability domain are reported in this Scientific Report).

Based on this information, EFSA concluded that under the applied approach, basic blue 7 should be regarded as genotoxic. Basic blue 7 consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 µg/kg bw per day should be used in case an RPA were to be established.

3.5. Brilliant green/C.I. basic green 1 (CAS 633-03-4) and leucobrilliant green (CAS 82-90-6)

**Brilliant green**
IUPAC name: [4-[4-(diethylamino)phenyl]-phenylmethylidene]cyclohexa-2,5-dien-1-yli
diethylazanium; hydrogen sulfate
EC number: 211-190-1
Molecular formula: C_{27}H_{34}N_{2}O_{4}S
Smiles code: \text{CCN(CC)C1=CC=C(C=C1)C(=C2C=CC(=N+(CC)C=C=C2)=C3CC=CC=CC3.0S(-O)(=-O)[O-]}

**Leucobrilliant green**
IUPAC name: 4-[4-(diethylamino)phenyl]-phenylmethyl-N,N-diethylaniline
EC number: -
Molecular formula: C_{27}H_{34}N_{2}
Smiles code: \text{CCN(CC)C1=CC=C(C=C1)C=C=C2=C=C=C2)C3=CC=CC=C3=C(C3)N(CC)CC}

3.5.1. Inclusion/exclusion from the guidance document

3.5.1.1. Q1: Are brilliant green and leucobrilliant green high potency carcinogens?

Brilliant green and leucobrilliant green (Figure 6) do not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of brilliant green (left) and leucobrilliant green (right)](image)

**Figure 6:** Chemical structure of brilliant green (left) and leucobrilliant green (right)
3.5.1.2. Q2: Are brilliant green and leucobrilliant green causing allergy?

Information in the REACH registration dossier of brilliant green on structural analogues indicates that brilliant green is suspected to be a dermal contact sensitiser. It is classified as skin sensitisser category 1 by the registrant.20

In literature, triphenylmethane dyes such as brilliant green and leucobrilliant green are indicated as weak sensitisers (Andersen and Maibach, 1983; Rietschel and Fowler, 2008). Bielicky and Novak (1969) described 11 patients with contact allergy to brilliant green, with eight patients being sensitive also to crystal violet and 6 of them were also sensitive to malachite green.

As no food or respiratory allergy was identified in the literature search for brilliant green and leucobrilliant green, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of brilliant green and leucobrilliant green.

3.5.1.3. Q3: Are brilliant green and leucobrilliant green causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.5.1.4. Conclusion

Based on the chemical structures of brilliant green and leucobrilliant green and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for these substances.

3.5.2. Toxicological screening value

3.5.2.1. Evaluation of genotoxicity

Brilliant green increased the frequency of mutations in bacteria (Salmonella Pullorum; Smith, 1962) and yeast (S. cerevisiae; Zmina and Pavlenko, 1990).

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, brilliant green is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the ISS Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q) SAR platform predicts that brilliant green is a mutagen (experimental value available or prediction with moderate reliability).21 Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as an alert for ‘in vivo mutagenicity (micronucleus)’ by ISS.

Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, mutations in thymidine kinase locus in mouse lymphoma cells, Syrian hamster embryo cell transformation, sex-linked recessive lethal test in Drosophila and sister chromatid exchange in mouse bone marrow cells (only predictions inside the applicability domain are reported in this Scientific Report).

No information was retrieved regarding leucobrilliant green in the scientific literature. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for in vitro mutagenicity (Ames), ‘in vivo mutagenicity (micronucleus)’ and structural alerts for genotoxic carcinogenicity by ISS.

Based on this information, EFSA concluded that under the applied approach, brilliant green and leucobrilliant green should be regarded as genotoxic. Both substances consequently belong to Group I as defined in the guidance document and a TSV of 0.0025 µg/kg bw per day should be used in case an RPA were to be established.

17 https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/17567/7/5/2
18 According to regulation (EC) No 1272/2008 substances shall be classfied as skin sensitisers (Category 1) (a) if there is evidence in humans that the substance can lead to sensitisation by skin contact in a substantial number of persons; or (b) if there are positive results from an appropriate animal test.
19 Regulation (EC) No 1272/2008 of the European Parliament and of the Council of 16 December 2008 on classification, labelling and packaging of substances and mixtures, amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006 (Text with EEA relevance) (OJ L 353, 31.12.2008, p. 1)
20 https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/17567/2/1
21 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.010.174
3.6. Basic blue 26 (CAS 2580-56-5)

IUPAC name: (4-((4-Anilino-1-naphthyl)(4-(dimethylamino)phenyl)methylene)cyclohexa-2,5-dien-1-ylidene)dimethylammonium chloride
EC number: 219-943-6
Molecular formula: C₃₃H₃₂N₃.Cl
Smiles code: CN(C)C1=CC(C=C1)C(=C2C=CC(=C[[NH+]C3=CC=CC=C4=C=C=C24)C5=CC=C(C=C5)N(C)C.[Cl-]

3.6.1. Inclusion/exclusion from the guidance document

3.6.1.1. Q1: Is basic blue 26 a high potency carcinogen?

Basic blue 26 (Figure 7) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of basic blue 26](image)

**Figure 7:** Chemical structure of basic blue 26

3.6.1.2. Q2: Is basic blue 26 causing allergy?

Basic blue 26 is a triarylmethane dye. Based on a read across with basic blue 7 (see Section 3.4.1.2), it is suspected to be a skin sensitiser.

As no food or respiratory allergy was identified in the literature search for basic blue 26, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of basic blue 26.

3.6.1.3. Q3: Is basic blue 26 causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.6.1.4. Conclusion

Based on the chemical structure of basic blue 26 and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for basic blue 26.
3.6.2. Toxicological screening value

3.6.2.1. Evaluation of genotoxicity

In the study conducted by Janik-Spiechowicz et al. (1997), basic blue 26 failed to induce mutagenicity in S. Typhimurium strains (Ames test), and did not cause the formation of micronuclei and sister chromatid exchanges in mice bone marrow cells in vivo.

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, basic blue 26 is a suspected mutagen as shown in different models. The Toolbox profiler Protein binding alerts for Chromosomal aberration by OASIS v1.1 gives an alert for mutagenicity. The CAESAR Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts with moderate reliability that basic blue 26 is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for in vitro mutagenicity (Ames), 'in vivo mutagenicity (micronucleus)' and structural alerts for genotoxic carcinogenicity by ISS.

Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, Ames test in S. Typhimurium (in vitro), Syrian hamster embryo cell transformation and sister chromatid exchange in mouse bone marrow cells and the comet assay in mouse (only predictions inside the applicability domain are reported in this Scientific Report).

One study on the genotoxic properties of basic blue 26 was identified which showed negative results. On the other hand, positive alerts were identified in several models. Since no evaluation of the quality of the studies is conducted in the applied methodology (see Section 2.2.1), EFSA followed a conservative approach and concluded that in the context of this evaluation, basic blue 26 should be regarded as genotoxic. This substance consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.7. Chloranil (CAS 118-75-2)

IUPAC name: 2,3,5,6-tetrachloro-1,4-benzoquinone
EC number: 204-274-4
Molecular formula: C₆Cl₄O₂
Smiles code: C1(=C(C(O)C(=C(C1O)Cl)Cl)Cl)Cl

3.7.1. Inclusion/exclusion from the guidance document

3.7.1.1. Q1: Is chloranil a high potency carcinogen?

Chloranil (Figure 8) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of chloranil](https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.018.131)

**Figure 8:** Chemical structure of chloranil

---

22 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.018.131
3.7.1.2. Q2: Is chloranil causing allergy?

Chloranil was found to be a skin sensitiser in a mouse local lymph node assay reported in the REACH registration dossier available on the ECHA website.\textsuperscript{23} It is classified as skin sensitiser category 1 by the registrant.\textsuperscript{24}

As no food or respiratory allergy was identified in the literature search for chloranil, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of chloranil.

3.7.1.3. Q3: Is chloranil causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.7.1.4. Conclusion

Based on the chemical structure of chloranil and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for chloranil.

3.7.2. Toxicological screening value

3.7.2.1. Evaluation of genotoxicity

Chloranil was indicated as one of the metabolites responsible for the genotoxicity and carcinogenicity of pentachlorophenol (PCP) (Dahlhaus et al., 1996; Zhu and Shan, 2009; Zhu et al., 2011).

In the study conducted by Dong et al. (2014), chloranil induced a significant increase of DNA and chromosomal damage (comet assay and micronucleus test) as well as histone H2AX phosphorylation (enzyme-linked immunosorbent assay (ELISA) and western blot analyses) in human hepatoma cells (HepG2). The authors concluded that the genotoxic effects probably occur through the induction of oxidative stress. Also other studies reported the ability of chloranil to cause oxidative base damage (Dahlhaus et al., 1996; Liu et al., 2011).

Chloranil was found to cause DNA and protein adducts both \textit{in vitro} (Lin et al., 2001; Jia et al., 2010) and \textit{in vivo}, following the administration of its parent compound (PCP) (Waidyanatha et al., 1994, Waidyanatha et al., 1996; Lin et al., 1997, 1999, 2002; Vaidyanathan et al., 2007).

Chloranil was considered to be non-mutagenic in S. Typhimurium and E. coli (Ames test) as reported in the REACH registration dossier available on the ECHA website.\textsuperscript{25} In the same dossier, a negative result was reported for an \textit{in vivo} mammalian erythrocyte micronucleus test (OECD 474).\textsuperscript{26} The available data are insufficient for classification.\textsuperscript{27}

Based on this information, EFSA concluded that under the applied approach, chloranil should be regarded as genotoxic. Chloranil consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 $\mu$g/kg bw per day should be used in case an RPA were to be established.

3.8. Crystal violet/gentian violet (CAS 548-62-9) and leucocrystal violet/leucogentian violet (CAS 603-48-5)

Crystal violet

IUPAC name: $[4\{-bis\{4\{dimethylamino\}phenyl\}methylidene\}cyclohexa-2,5-dien-1-ylidene\}dimethylazanium;chloride$

EC number: 208-953-6

Molecular formula: C\textsubscript{25}H\textsubscript{30}ClN\textsubscript{3}

Smiles code: CN(C)C1=CC=C(C=C1)C(-C2C=CC(-[N+])(C)C=C2)C3=CC=C(C=C3)N(C)C.[Cl-]

\textsuperscript{23} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/2069/7/5/2
\textsuperscript{24} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/2069/2/1
\textsuperscript{25} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/2069/7/7/2
\textsuperscript{26} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/2069/7/7/5
\textsuperscript{27} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/2069/2/2
Leucocrystal violet
IUPAC name: 4-[bis[4-(dimethylamino)phenyl]methyl]-N,N-dimethylaniline
EC number: 210-043-9
Molecular formula: C₂₅H₃₁N₃
Smiles code: CN(C)C1–CC–C(C=C1)C(C2–CC–C(C=C2)N(C)C)C3–CC–C(C=C3)N(C)C

3.8.1. Inclusion/exclusion from the guidance document

3.8.1.1. Q1: Are crystal violet and leucocrystal violet high potency carcinogens?
Crystal violet and leucocrystal violet (Figure 9) do not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of crystal violet and leucocrystal violet](image)

Figure 9: Chemical structure of crystal violet (up) and leucocrystal violet (bottom)

3.8.1.2. Q2: Are crystal violet and leucocrystal violet causing allergy?
The JECFA evaluated crystal violet at its 78th meeting in 2013 and noted that crystal violet is shown to cause dermal irritation/sensitisation (FAO/WHO, 2014).

Inconclusive results regarding skin sensitisation are reported in the dossier of crystal violet available on the ECHA website and no self-classification regarding skin sensitisation has been proposed by the registrant.²⁸

²⁸ [Website link](https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/10024/7/5/2)
Triphenylmethane dyes such as crystal violet and leucocystal violet are weak sensitisers and are capable of producing phototoxic dermatitis (Andersen and Maibach, 1983; Rietschel and Fowler, 2008). Cross-reactivity with some triphenylmethane dyes was described by Bielicky and Novak (1969) in 11 patients with contact allergy to the triphenylmethane dye brilliant green, of which 8 patients showed cross-reactivity with crystal violet, and 6 of these patients also showed cross-reactivity with malachite green.

As no food or respiratory allergy was identified in the literature search for crystal violet and leucocystal violet, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of crystal violet and leucocystal violet.

3.8.1.3. Q3: Are crystal violet and leucocystal violet causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.8.1.4. Conclusion

Based on the chemical structures of crystal violet and leucocystal violet and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for these substances.

3.8.2. Toxicological screening value

3.8.2.1. Evaluation of genotoxicity

Several studies reported that crystal violet is mutagenic towards bacteria (Wild and Hinshelwood, 1956; Smith, 1962; Takahashi, 1972; Fujita et al., 1976; Bonin et al., 1981; Malachová et al., 2006). Moreover, the compound was found to enhance the mutagenic potency of UV (Witkin, 1961; Hill and Feiner, 1964; Levin et al., 1982).

In the onion root tip, crystal violet did not induce any chromosome mutations (Battaglia, 1950).

In the study by Au et al. (1979), crystal violet was negative in the Ames test, as well as in cytogenetic assays (Chinese hamster ovary cells in vitro, the chicken-embryo and mouse-bone-marrow cells in vivo), but caused repairable DNA damage in the Rosenkranz bacterial assay. However, no further information regarding this test was identified. In another study, crystal violet showed clastogenic property in different mammalian cell lines in vitro (Au et al., 1978). Positive genotoxic effects were also observed in the comet assay performed on leukocytes from rat blood exposed in vitro to crystal violet (Diaz Gomez and Castro, 2013).

In the review published by Docampo and Moreno (1990), crystal violet was considered as mutagenic and clastogenic.

Negative results were reported by NTP29 for in vitro cytogenetics (sister chromatid exchange and chromosomal aberrations) and for mutagenicity in Drosophila. Equivocal results were reported for the Ames test.

No toxicological information was retrieved in the scientific literature regarding leucocystal violet. Therefore, the outcome from computational toxicology was taken into consideration. As indicated on the ECHA website, leucocystal violet is a suspected mutagen as shown in different models. The KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predict with moderate reliability that leucocystal violet is a mutagen.30 Alerts for DNA binding by OECD were identified in the QSAR toolbox, as well as alerts for in vitro mutagenicity (Ames), in vivo mutagenicity (micronucleus) and structural alerts for genotoxic carcinogenicity by ISS. Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ames test in S. Typhimurium (in vitro), mutations in thymidine kinase locus in mouse lymphoma cells, Syrian Hamster embryo cell transformation, sister chromatid exchange in mouse bone marrow cells and the comet assay in mouse (only predictions inside the applicability domain are reported in this Scientific Report).

Based on this information, EFSA concluded that under the applied approach, crystal violet and leucocystal violet should be regarded as genotoxic. Both substances consequently belong to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

---

29 https://ntp.niehs.nih.gov/testing/status/agents/ts-10008-r.html
30 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.009.131
3.9. Dichlone (CAS 117-80-6)

IUPAC name: 2,3-dichoronaphthalene-1,4-dione
EC number: 204-210-5
Molecular formula: C\textsubscript{10}H\textsubscript{4}Cl\textsubscript{2}O\textsubscript{2}
Smiles code: C1\textsubscript{=C}C\textsubscript{2}C(=C1)C(=O)C(=C(C2=O)Cl)Cl

3.9.1. Inclusion/exclusion from the guidance document

3.9.1.1. Q1: Is dichlone a high potency carcinogen?

Dichlone (Figure 10) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of dichlone](image)

3.9.1.2. Q2: Is dichlone causing allergy?

Two studies are reported in the REACH registration dossier available on the ECHA website. From an in vitro keratinocyte activation assay (LuSens), it was concluded that dichlone has a keratinocyte activating potential.\textsuperscript{31} From a direct peptide reactivity assay (DPRA), it was concluded that dichlone shows a high chemical reactivity.\textsuperscript{32} Dichlone is classified as skin sensitisation category 1 by the registrant.\textsuperscript{33}

As no food or respiratory allergy was identified in the literature search for dichlone, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of dichlone.

3.9.1.3. Q3: Is dichlone causing blood dyscrasias?

Haematology was investigated in a subacute toxicity study in rats (REACH registration dossier), however no conclusion regarding blood dyscrasias could be drawn from this study.\textsuperscript{34}

3.9.1.4. Conclusion

Based on the chemical structure of dichlone and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for dichlone.

3.9.2. Toxicological screening value

3.9.2.1. Evaluation of genotoxicity

Dichlone showed high mutagenicity in S. Typhimurium strains (Ames test) as reported by Hakura et al. (1994), whereas it was negative in the study by Onodera et al. (1982).

\textsuperscript{31} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/7/5/2?documentUUID=2bb75381-66a4-4d4d-89a5-f1047dd0e026
\textsuperscript{32} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/7/5/2
\textsuperscript{33} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/2/1
\textsuperscript{34} https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/7/6/2
Dichlone was not mutagenic in *S. Typhimurium/E. coli* (Ames test) in the absence and the presence of metabolic activation as reported in the REACH registration dossier available on the ECHA website. The available data are insufficient for classification.

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. Alerts for DNA binding by OECD and by OASIS v.1.3 were identified in the QSAR toolbox as well as DNA alerts for Ames test, micronucleus and chromosomal aberrations by OASIS v. 1.3 and alerts for *in vitro* mutagenicity (Ames), *in vivo* mutagenicity (micronucleus) and structural alerts for genotoxic carcinogenicity by ISS.

Based on this information, EFSA concluded that under the applied approach, dichlone should be regarded as genotoxic. This substance consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

### 3.10. Ethyl violet (CAS 25275-06-3)

IUPAC name: [4-{bis[4-(diethylamino)phenyl]methylidene}cyclohexa-2,5-dien-1-yli dene]-diethylazanium

EC number: 246-781-3

Molecular formula: C₃₁H₄₂N₃⁺

Smiles code: CCN(CC)C₁=C=CCCC(CCCCCCCCCCCCCCCCCC)C=CC=C(C=C₃)N(CC)CC

#### 3.10.1. Inclusion/exclusion from the guidance document

**3.10.1.1. Q1: Is ethyl violet a high potency carcinogen?**

Ethyl violet (Figure 11) does not belong to the chemical classes defined as high potency carcinogens.

**Figure 11:** Chemical structure of ethyl violet

**3.10.1.2. Q2: Is ethyl violet causing allergy?**

Ethyl violet is a triphenylmethane dye and therefore suspected to be a skin sensitiser (see Section 3.5.1.2).

As no food or respiratory allergy was identified in the literature search for ethyl violet, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of ethyl violet.

35 https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/7/7/2

36 https://www.echa.europa.eu/web/guest/registration-dossier/-/registered-dossier/16993/2/2
3.10.1.3. Q3: Is ethyl violet causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.10.1.4. Conclusion

Based on the chemical structure of ethyl violet and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for ethyl violet.

3.10.2. Toxicological screening value

3.10.2.1. Evaluation of genotoxicity

Lewis and Indig (2001) reported that ethyl violet efficiently binds to DNA, mediating its photochemical destruction.

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, ethyl violet is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in VEGA (Q)SAR platform predicts on the basis of experimental values that ethyl violet is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for *in vitro* mutagenicity (Ames), *in vivo* mutagenicity (micronucleus) and structural alerts for genotoxic carcinogenicity by ISS.

Based on this information, EFSA concluded that under the applied approach, ethyl violet should be regarded as genotoxic. This substance consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 µg/kg bw per day should be used in case an RPA were to be established.

3.11. Methylene blue (CAS 61-73-4)

IUPAC name: [7-(dimethylamino)phenothiazin-3-ylidene]-dimethylazanium;chloride

EC number: 200-515-2

Molecular formula: C_{16}H_{18}ClN_{3}S

Smiles code: CN(C)C1=C=C2=C(C=C1)N=C3C=CC=[N+](C)(C)C=C3S2.[Cl-]

3.11.1. Inclusion/exclusion from the guidance document

3.11.1.1. Q1: Is methylene blue a high potency carcinogen?

Methylene blue (Figure 12) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of methylene blue](image)

**Figure 12:** Chemical structure of methylene blue

3.11.1.2. Q2: Is methylene blue causing allergy?

No alerts for skin sensitisation are reported on the ECHA website. Also in the QSAR toolbox no alerts were reported for skin sensitisation.

A few very rare case reports regarding methylene blue-induced anaphylactic reactions upon injection in surgery patients were identified in the scientific literature (Dewachter et al., 2005, 2011; Jangjoo et al., 2010). These reactions were IgE mediated and probably caused by a conjugation of methylene blue as hapten to a protein.

---

37 [https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.042.514](https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.042.514)

38 [https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.000.469](https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.000.469)
As no food or respiratory allergy nor skin allergy was identified in the literature search for methylene blue, and concern for anaphylactic reactions upon oral exposure is low, there are no safety concerns with respect to allergenicity of methylene blue.

3.11.1.3. Q3: Is methylene blue causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.11.1.4. Conclusion

Based on the chemical structure of methylene blue and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for methylene blue.

3.11.2. Toxicological screening value

3.11.2.1. Evaluation of genotoxicity

Methylene blue was found to induce mutations in different bacteria strains (Smith, 1962; Webb and Hass, 1984). In one study, methylene blue was efficient in producing yeast mutants (Mitchell and Bevan, 1973), while in others it was not (Nagai, 1963; Morita and Mifuchi, 1965). Morita and Mifuchi (1965) reported a low increase in the mutation rate (1.2–4.5%) in yeast at pH 9.0, but not at pH values from 5.0 to 7.0.

Many studies reported that, in the presence of light, methylene blue can generate oxidative DNA damage in bacteria (Czeczot et al., 1991), yeast (Meniel and Waters, 1999) and mammalian cells (Zhang et al., 2000; Slamenova et al., 2002, 2003; Lazarova et al., 2006).

DNA damage and chromosome aberrations were also found in plants exposed to methylene blue (Sushil and Natarajan, 1965; Li et al., 2002).

Genotoxic effects were detected in mammalian cells using the comet assay (Masannat et al., 2009) and the mouse lymphoma TK assay (Wagner et al., 1995). In vivo, methylene blue gave negative results in the sister chromatid exchange test (Speit, 1982) and in the micronucleus assay (Sychyova et al., 2007; Masannat et al., 2009).

Based on this information, EFSA concluded that under the applied approach, methylene blue should be regarded as genotoxic. This substance consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.12. New methylene blue/victoria blue R (CAS 2185-86-6)

IUPAC name: [4-[bis[4-(dimethylamino)phenyl]methylidene]naphthalen-1-ylidene]-ethylazanium; chloride
EC number: 218-572-7
Molecular formula: C29H32ClN3
Smiles code: CC[NH+]=C1C-CC(-C(C2-CC=C(C=C2))N(C)C3=CC=C(C=C3)N(C)C4=CC=C(C14).[Cl-]

3.12.1. Inclusion/exclusion from the guidance document

3.12.1.1. Q1: Is victoria blue R a high potency carcinogen?

Victoria blue R (Figure 13) does not belong to the chemical classes defined as high potency carcinogens.
3.12.1.2. Q2: Is victoria blue R causing allergy?

Victoria blue R is a triarylmethane dye. Based on a read across with basic blue 7 (see Section 3.4.1.2), victoria blue R is suspected to be a skin sensitiser. As no food or respiratory allergy was identified in the literature search for victoria blue R, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of victoria blue R.

3.12.1.3. Q3: Is victoria blue R causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.12.1.4. Conclusion

Based on the chemical structure of victoria blue R and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for victoria blue R.

3.12.2. Toxicological screening value

3.12.2.1. Evaluation of genotoxicity

Victoria blue R significantly increased the frequency of both cytoplasmic and nuclear mutants in yeast (S. cerevisiae) (Pavlenko and Zimina, 1983; Zimina and Pavlenko, 1990).

Lewis and Indig (2001) reported that victoria blue R mediates the photochemical destruction of DNA in tumour cells.

In one in vivo study, oral administration of victoria blue R induced chromosome aberrations in the bone marrow of male rats (Chesnokov et al., 1979).

Based on this information, EFSA concluded that under the applied approach, victoria blue R should be regarded as genotoxic. Victoria blue R consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.13. Nile blue (CAS 2381-85-3)

IUPAC name: [9-(diethylamino)benzo[a]phenoxazin-5-ylidene]azanium; chloride
EC number: 219-181-4
Molecular formula: C_{20}H_{20}ClN_{3}O
Smiles code: CCN(CC)C1=C-C2=C(C=1)N=C3C4=CC=CC=C4C(=[NH2+])C=C3O2.[Cl-]
3.13.1. Inclusion/exclusion from the guidance document

3.13.1.1. Q1: Is Nile blue a high potency carcinogen?

Nile blue (Figure 14) does not belong to the chemical classes defined as high potency carcinogens.

3.13.1.2. Q2: Is Nile blue causing allergy?

As no food or respiratory allergy nor skin allergy was identified in the literature search for Nile blue, there are no safety concerns with respect to allergenicity of Nile blue.

3.13.1.3. Q3: Is Nile blue causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.13.1.4. Conclusion

Based on the chemical structure of Nile blue and the lack of evidence that Nile blue is causing allergy or blood dyscrasias, the guidance document can be applied to establish an RPA for Nile blue.

3.13.2. Toxicological screening value

3.13.2.1. Evaluation of genotoxicity

Nagai (1962) reported mutagenicity of Nile blue in yeast and several authors reported DNA binding (e.g. Zhao et al., 2002; Mitra et al., 2009; Gattuso et al., 2016).

Given the limited information identified in the scientific literature, EFSA took into consideration the outcome from computational toxicology. As indicated on the ECHA website, Nile blue is a suspected mutagen as shown in different models. The Toolbox profilers ‘DNA alerts for AMES, MN and CA by OASIS v.1.3’ and ‘in vitro mutagenicity (Ames test) alerts by ISS’ give alerts for mutagenicity. The CAESAR Mutagenicity model, the ISS Mutagenicity model and the KNNA Mutagenicity model in the VEGA (Q)SAR platform predicts with good to moderate reliability that Nile blue is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for in vitro mutagenicity (Ames), in vivo mutagenicity (micronucleus) and structural alerts for genotoxic carcinogenicity by ISS.

Based on this information EFSA concluded that under the applied approach, Nile blue should be regarded as genotoxic. Nile blue consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 µg/kg bw per day should be used in case an RPA were to be established.

3.14. Pararosaniline base (CAS 25620-78-4\textsuperscript{40})

- IUPAC name: tris(4-aminophenyl)methanol
- EC number: 207-395-0
- Molecular formula: C\textsubscript{19}H\textsubscript{19}N\textsubscript{3}O
- Smiles code: C1=CC(=CC=C1C(=C(C=C2)(C=C=C2)N)(C3=CC(=C(C=C3)N)O)N

\textsuperscript{39} https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.017.439

\textsuperscript{40} CAS number as provided by EC; however EFSA noted that the CAS number 467-62-9 is more often used for this compound
3.14.1. Inclusion/exclusion from the guidance document

3.14.1.1. Q1: Is pararosaniline base a high potency carcinogen?

Pararosaniline base (Figure 15) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of pararosaniline base](image)

**Figure 15:** Chemical structure of pararosaniline base

3.14.1.2. Q2: Is pararosaniline base causing allergy?

As indicated on the ECHA website, pararosaniline base is a suspected skin sensitiser as predicted with moderate reliability with the CAESAR skin sensitisation model in the VEGA (Q)SAR platform. Moreover, a positive prediction was obtained for 'Allergic Contact Dermatitis in Guinea Pig and Human' in the Danish QSAR database. However, no alerts were reported for skin sensitisation in the QSAR toolbox.

As no food or respiratory allergy was identified in the literature search for pararosaniline base, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of pararosaniline base.

3.14.1.3. Q3: Is pararosaniline base causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.14.1.4. Conclusion

Based on the chemical structure of pararosaniline base and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for pararosaniline base.

3.14.2. Toxicological screening value

3.14.2.1. Evaluation of genotoxicity

No papers were identified in the scientific literature on the genotoxicity of pararosaniline base.

As indicated on the ECHA website, pararosaniline base is a suspected mutagen as shown in different models. The Toolbox profiler *in vitro* mutagenicity (Ames test) alerts by ISS gives an alert for mutagenicity. The ISS Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts with moderate reliability that pararosaniline base is a mutagen. Alerts for DNA binding by OECD were identified in the QSAR toolbox as well as alerts for *in vitro* mutagenicity (Ames), *in vivo* mutagenicity (micronucleus) and structural alerts for genotoxic carcinogenicity by ISS. Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, Ames test in S. Typhimurium (*in vitro*), chromosome

41 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AII-100.006.724
aberrations in Chinese hamster lung cells, unscheduled DNA synthesis in rat hepatocytes, sister chromatid exchange in mouse bone marrow cells and the comet assay in Mouse (only predictions inside the applicability domain are reported in this Scientific Report).

Based on this information, EFSA concluded that under the applied approach, pararosaniline should be regarded as genotoxic. Pararosaniline base consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.15. Potassium permanganate (CAS 7722-64-7)

IUPAC name: potassium oxido(trioxo)manganese
EC number: 231-760-3
Molecular formula: KMnO₄
Smiles code: [O-][Mn](=O)(=O)=O.[K+]

3.15.1. Inclusion/exclusion from the guidance document

Potassium permanganate (Figure 16) is an inorganic compound. The CONTAM Panel agreed at the 83rd Panel meeting⁸ that inorganic substances should be excluded from the guidance document (see Section 2.2.1). Therefore, the guidance document cannot be applied to potassium permanganate and no TSV can be assigned to this compound.

![Chemical structure of potassium permanganate](image)

**Figure 16:** Chemical structure of potassium permanganate

3.16. Proflavine (CAS 92-62-6) and proflavine hydrochloride (CAS 952-23-8)

**Proflavine**
IUPAC name: acridine-3,6-diamine
EC number: 202-172-4
Molecular formula: C₁₃H₁₁N₃
Smiles code: C1=CC(-CC2=NC3=C(C=C(C=C3)N)C=C21)N

**Proflavine hydrochloride**
IUPAC name: acridine-3,6-diamine;hydrochloride
EC number: 213-459-9
Molecular formula: C₁₃H₁₂ClN₃
Smiles code: C1=CC(-CC2=NC3=C(C=C(C=C3)N)C=C21)N.Cl

3.16.1. Inclusion/exclusion from the guidance document

3.16.1.1. Q1: Are proflavine and proflavine hydrochloride high potency carcinogens?

Proflavine and proflavine hydrochloride (Figure 17) do not belong to the chemical classes defined as high potency carcinogens.
3.16.1.2. Q2: Are proflavine and proflavine hydrochloride causing allergy?

Proflavine-induced human contact sensitivity is well documented and allergic skin reactions may be severe (Plakas et al., 1999).

No information was identified for proflavine hydrochloride, but proflavine dihydrochloride has been reported to cause ACD (Rietschel and Fowler, 2008).

As no food or respiratory allergy was identified in the literature search for proflavine and proflavine hydrochloride, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of proflavine and proflavine hydrochloride.

3.16.1.3. Q3: Are proflavine and proflavine hydrochloride causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.16.1.4. Conclusion

Based on the chemical structures of proflavine and proflavine hydrochloride and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for proflavine and proflavine hydrochloride.

3.16.2. Toxicological screening value

3.16.2.1. Evaluation of genotoxicity

Proflavine induced significant mutagenicity in bacteriophages (Demars, 1953; Orgel and Brenner, 1961; Drake, 1964; Hessler, 1965; Ritchie, 1965), bacteria (Dean and Hinshelwood, 1951; Randall et al., 1964; Ferguson et al., 1991; Sun and Stahr, 1993) and yeast (Marcovich, 1953). Mutant RNA viruses were observed after co-exposure to proflavine and light (Gendon, 1963).

Proflavine induced chromosome breakages in Vicia fava (Ockey, 1957) and increases the frequency of sister chromatid exchanges in both human lymphocytes and Chinese hamster ovary cells (Morgan and Crossen, 1982). In human fibroblasts, proflavine affected DNA synthesis, but did not induce any unscheduled DNA synthesis (Benigni et al., 1990).

No studies were identified in the scientific literature on the genotoxicity of proflavine hydrochloride. Therefore, the outcome from computational toxicology was taken into consideration. As indicated on the ECHA website, proflavine hydrochloride is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the ISS Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts based on experimental values that proflavine hydrochloride is a mutagen. It is also a mutagen according to ISSSTY database.42

Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, Ames test in S. Typhimurium (in vitro), chromosome aberrations in Chinese hamster lung cells, unscheduled DNA synthesis in rat hepatocytes, Syrian hamster embryo cell transformation, sister chromatid exchange in mouse bone marrow cells and the comet assay in Mouse (only predictions inside the applicability domain are reported in this Scientific Report).

Based on this information, EFSA concluded that under the applied approach, proflavine and proflavine hydrochloride should be regarded as genotoxic. Both substances consequently belong to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

42 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.012.236
3.17. Rhodamine 6G (CAS 989-38-8)

**IUPAC name:** ethyl 2-[3-(ethylamino)-6-ethylimino-2,7-dimethylxanthen-9-yl]benzoate hydrochloride  
**EC number:** 213-584-9  
**Molecular formula:** C$_{28}$H$_{31}$ClN$_2$O$_3$  
**Smiles code:** CCNC1=O(C=C2CC=C(NCC)C(-C3=C2C4=-C(C=O)OCC)C)C.Cl

3.17.1. Inclusion/exclusion from the guidance document

3.17.1.1. Q1: Is rhodamine 6G a high potency carcinogen?

Rhodamine 6G (Figure 18) does not belong to the chemical classes defined as high potency carcinogens.

![Figure 18: Chemical structure of rhodamine 6G](image)

3.17.1.2. Q2: Is rhodamine 6G causing allergy?

Although no alerts for skin sensitisation are reported on the ECHA website, and no alerts for skin sensitisation were found in the QSAR toolbox, rhodamine 6G has been reported to cause contact sensitisation (Albert, 1997).

As no food or respiratory allergy was identified in the literature search for rhodamine 6G, and there is no concern of reactivation of ACD or SCD upon oral exposure of individuals with an existing contact allergy to a dye (see Section 2.1.2), there are no safety concerns with respect to allergenicity of rhodamine 6G.

3.17.1.3. Q3: Is rhodamine 6G causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.17.1.4. Conclusion

Based on the chemical structure of rhodamine 6G and the absence of safety concerns upon oral exposure with respect to allergenicity or blood dyscrasias, the guidance document can be applied to establish an RPA for rhodamine 6G.

3.17.2. Toxicological screening value

3.17.2.1. Evaluation of genotoxicity

Rhodamine 6G was found to induce mutations in bacteria (Nestmann et al., 1979), yeast (Carignani et al., 1977) and DNA damage (single-strand breaks) in Chinese hamster ovary cells, as detected by alkaline sucrose sedimentation (Nestmann et al., 1979).

In the NTP study of rhodamine 6G (NTP, 1989), there was equivocal evidence of genotoxicity activity. In particular, the compound gave negative results in different S. Typhimurium strains (Ames test). In the mouse lymphoma assay, rhodamine 6G was negative in the presence of exogenous metabolic activation (S9), whereas positive results were reported in the absence of S9. Sister chromatid exchanges and chromosomal aberrations were induced in Chinese hamster ovary cells in the presence, but not the absence, of S9.

---

43 [https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.012.350](https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.012.350)
Based on this information EFSA concluded that under the applied approach, rhodamine 6G should be regarded as genotoxic. Rhodamine 6G consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.18. Trypan red (CAS 574-64-1)

IUPAC name: pentasodium;3-amino-4-[[4-[4-[[2-amino-3,6-disulfonatonaphthalen-1-yl]diazenyl]-3-sulfonatophenyl]phenyl]diazenyl]naphthalene-2,7-disulfonate

EC number: 209-372-0

Molecular formula: C₃₂H₁₉N₆Na₅O₁₅S₅

Smiles code: C1=CC(C=C1C2=CC(C=C2CN3C4C(C(C=C4C3N)S(O)(=O)[O-])S(=O)(=O)[O-])S(=O)(=O)[O-])NC5C6C=CC=C(C5N)S(=O)(=O)[O-])S(=O)(=O)[O-][Na+][Na+][Na+]\[Na+\][Na+]

3.18.1. Inclusion/exclusion from the guidance document

3.18.1.1. Q1: Is trypan red a high potency carcinogen?

Trypan red (Figure 19) does not belong to the chemical classes defined as high potency carcinogens.

![Chemical structure of trypan red](image-url)

**Figure 19:** Chemical structure of trypan red
3.18.1.2. Q2: Is trypan red causing allergy?

No alerts for skin sensitisation are reported on the ECHA website and no alerts were found in the QSAR toolbox.
As no food or respiratory allergy nor skin allergy was identified in the literature search for trypan red, there are no safety concerns with respect to allergenicity of trypan red.

3.18.1.3. Q3: Is trypan red causing blood dyscrasias?

No studies regarding blood dyscrasias were identified in the literature search.

3.18.1.4. Conclusion

Based on the chemical structure of trypan red and the lack of evidence that trypan red is causing allergy or blood dyscrasias, the guidance document can be applied to establish an RPA for trypan red.

3.18.2. Toxicological screening value

3.18.2.1. Evaluation of genotoxicity

No toxicological information was retrieved in the scientific literature regarding trypan red following the approach described in Section 2.2.1. Therefore, the outcome from computational toxicology was taken into consideration. As indicated on the ECHA website, trypan red is a suspected mutagen as shown in different models. The CAESAR Mutagenicity model, the ISS Mutagenicity model, the KNN Mutagenicity model and the SARPY Mutagenicity model in the VEGA (Q)SAR platform predicts that trypan red is a mutagen with moderate or good reliability. Alerts for DNA binding by OASIS v1.3 and OECD were identified in the QSAR toolbox as well as an alert for ‘in vivo mutagenicity (micronucleus)’ by ISS. Positive alerts were also reported in the Danish QSAR database using the battery algorithm for Ashby structural alerts, Ames test in S. Typhimurium (in vitro), chromosome aberrations in Chinese hamster lung cells, unscheduled DNA synthesis in rat hepatocytes, Syrian hamster embryo cell transformation, sister chromatid exchange in mouse bone marrow cells and the comet assay in mouse (only predictions inside the applicability domain are reported in this Scientific Report).

Based on this information, EFSA concluded that under the applied approach, trypan red should be regarded as genotoxic. Trypan red consequently belongs to Group I as defined in the guidance document and a TSV of 0.0025 μg/kg bw per day should be used in case an RPA were to be established.

3.19. Summary (Table 2)

Table 2: Overview of the evaluation for each dye

| Substance | Part I | Part II |
|-----------|--------|---------|
|           | Q1(a)  | Q2(a)  | Q3(a) | Excluded from guidance document? | Q4(a) | Q5(a) | TSV (μg/kg bw per day) |
| Acriflavine | No | No | No | No | Yes | – | 0.0025 |
| 3-Aminoacridine | No | No | No | No | Yes | – | 0.0025 |
| Aminoacridine | No | No | No | No | Yes | – | 0.0025 |
| Azure blue/ultramarine | –(b) | – | – | Yes | – | – | – |
| Basic blue 7/victoria pure blue BO | No | No | No | No | Yes | – | 0.0025 |
| Brilliant green/C.I. basic green 1 | No | No | No | No | Yes | – | 0.0025 |
| Leucobrilliant green | No | No | No | No | Yes | – | 0.0025 |
| C.I. basic blue 26 | No | No | No | No | Yes | – | 0.0025 |
| Chloranil | No | No | No | No | Yes | – | 0.0025 |

---

44 https://www.echa.europa.eu/web/guest/information-on-chemicals/annex-iii-inventory/-/dislist/details/AIII-100.008.521
4. Conclusions

EFSA evaluated whether the guidance document is applicable to the dyes listed in Table 1 of this Scientific Report and concluded the following:

- Acriflavine, 3-aminoacridine, aminoacridine, basic blue 7, brilliant green, leucobrilliant green, C.I. basic blue 26, chloranil, crystal violet, leucocrystal violet, dichlone, ethyl violet, methylene blue, new methylene blue, Nile blue, pararosaniline base, proflavine, proflavine hydrochloride, rhodamine 6G and trypan red are covered by the guidance document and belong to group I. A TSV of 0.0025 μg/kg bw per day is applicable.

- Azure blue and potassium permanganate are excluded from the guidance document since they are inorganic compounds.

References

Acharya N, Abu-Nasr NF, Kawaguchi G, Imai M and Yamamoto K, 2007. Frameshift mutations produced by 9-aminoacridine in wild-type, uvrA and recA strains of _Escherichia coli_; specificity within a hotspot. Journal of Radiation Research, 48, 361–368. https://doi.org/10.1269/jrr.07036

Alba P, Ferres MD and Xamena N, 1983. Genotoxicity of acridine orange and acriflavine in _Drosophila melanogaster_. Mutation Research, 121, 199–203.

Albert RE, 1997. Allergic contact sensitizing chemicals as environmental carcinogens. Environmental Health Perspectives, 105, 940–948. https://doi.org/10.1289/ehp.97105940

Ali AMM, Ahmed KA, Abdel-Wahab SM and Hamouda MH, 1978. Induction of acriflavine mutations in _Rhizobium trifoli_. and effectiveness of mutants. Egyptian Journal of Microbiology, 13, 71–80.

Andersen KE and Maibach HI, 1983. Drugs Used Topically. In: de Weck AL and Bundgaard H (eds.). Allergic Reactions to Drugs. Springer-Verlag, Berlin, Heidelberg. pp. 313–377.

Aoki S, Ito-Kuwa S, Nakamura K and Nakamura Y, 2005. Cell biology of respiration-deficient mutants of _Candida albicans_. Japanese Journal of Medical Mycology, 46, 243–247.

Ariett CF, 1957. Induction of cytoplasmic mutation in _Aspergillus nidulans_. Nature, 179, 1251–1252.

Au W, Pathak S, Collie CJ and Hsu TC, 1978. Cytogenetic toxicity of gentian violet and crystal violet on mammalian cells in vitro. Mutation Research, 58, 269–276.
Au W, Butler MA, Bloom SE and Matney TS, 1979. Further study of the genetic toxicity of gentian violet. Mutation Research, 66, 103–112.

Baker RS, Mitchell GA, Meher-Homji KM and Podobna E, 1983. Sensitivity of two Chinese hamster cell lines to SCE induction by a variety of chemical mutagens. Mutation Research, 118, 103–116.

Ball C and Roper JA, 1966. Studies on the inhibition and mutation of Aspergillus nidulans by acridines. Genetics Research, 7, 207–221.

Battaglia E, 1950. New substances which induce chromosome fragmentation. Pubbl Staz Zool Napoli Suppl, 22, 125–157.

Beikirch H, 1977. Induction of unscheduled DNA synthesis by chemical mutagens in testicular cells of the mouse in vitro. Archives of Toxicology, 37, 195–201.

Ben-Hur E and Ben-Ishai R, 1971. DNA repair in UV light irradiated HeLa cells and its reversible inhibition by hydroxy urea. Photochemistry and Photobiology, 13, 337–346. https://doi.org/10.1111/j.1751-1097.1971.tb00121.x

Benigni R, Calcagnile A, Giuliani A and Leopardi P, 1990. Inhibition of replicative DNA synthesis and induction of DNA repair in human fibroblasts by the intercalating drugs proflavine and 9-aminoacridine. Journal of Toxicology and Environmental Health, 31, 117–124.

Bilicky T and Novak M, 1969. Contact-group sensitization to triphenylmethane dyes. Gentian violet, brilliant green, and malachite green. Archives of Dermatolog, 100, 540–543.

Bonin AM, Farquharson JB and Baker RSU, 1981. Mutagenicity of arylmethane dyes in Salmonella. Mutation Research, 89, 21–34.

Brown BR, Firth III WJ and Yielding LW, 1980. Acridine structure correlated with mutagenic activity in Salmonella. Mutation Research, 72, 373–388.

Calendi E, Bassu MC, Congiu AM and Fugo G, 1974. Interaction of acridine derivatives with nucleic acids. II. Mutagenic activity on bacteria and on chromosomes. Giornale di Microbiologia, 22, 57–60.

Carignani G, Lancashire WE and Griffiths DE, 1977. Extra chromosomal inheritance of rhodamine 6G resistance in Saccharomyces cerevisiae. Molecular and General Genetics, 151, 49–56.

Chesnokov AN, Verenikina BI and Selizuhtskii GV, 1979. Gonadotoxic and mutagenic effect of the triarylmethanes in basic blue K and basic violet K. Gigiena i sanitariia, 8, 70–71.

Cezczot H, Tudek B, Lambert B, Laval J and Boiteux S, 1991. Escherichia coli Fpg protein and UvrABC endonuclease repair DNA damage induced by methylene blue plus visible light in vivo and in vitro. Journal of Bacteriology, 173, 3419–3424.

Dahlihaus M, Almstata E, Henschke P, Luttgert S and Apel KE, 1996. Oxidative DNA lesions in V79 cells mediated by pentachlorophenol metabolites. Archives of Toxicology, 70, 457–460. https://doi.org/10.1007/s002040050299

D’Amato F, 1952. Mutagenic activity of acridines. XXXIII-LI. Caryologia, 4, 388–413. https://doi.org/10.1080/00087114.1952.10797548

Dean ACR and Hinshelwood C, 1951. Induced and other variations in bacterial cultures. II. General survey of changes produced in Bact. lactis aerogenes (Aerobacter aerogenes) by ultra-violet light and some other mutagenic agents. Journal of the Chemical Society (London), 1951, 1159–1168.

Deluca JG, Kravetski J and Skopek TR, 1977. 9 Aminocaridine. A frameshift mutagen for Salmonella typhimurium TA 1537 inactive at the hgprt locus in human lymphoblasts. Mutation Research, 42, 327–330.

Demars RJ, 1953. Chemical mutagenesis in bacteriophage T2. Nature, 172, 964.

Demerec M, Bertani G and Flint J, 1951. A survey of chemicals for mutagenic action on Escherichia coli. Bacteriology, 173, 3419–3424.

Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A and Mouton-Faivre C, 2011. Severe anaphylactic shock with methylene blue. Annals of Allergy, Asthma and Immunology, 107, 149–150, table of contents. https://doi.org/10.1086/281660

Dewachter P, Castro S, Nicaise-Roland P, Chollet-Martin S, Le Beller C, Lillo-le-Louet A and Mouton-Faivre C, 2011. Anaphylactic reaction after methylene blue-treated plasma transfusion. British Journal of Anaesthesia, 106, 687–689. https://doi.org/10.1093/bja/aer009

Díaz-Gomez MI and Castro JA, 2013. Genotoxicity in leukocytes by blood chemophrophylaxis with Gentian Violet and its prevention with antioxidants. Acta Bioquimica Clinica Latinoamericana, 47, 719–726.

Docampo R and Moreno SNJ, 1990. The metabolism and mode of action of gentian violet. Drug Metabolism Reviews, 22, 161–178.

Dong H, Xu D, Hu L, Li S, Song E and Song Y, 2014. Evaluation of N-acetyl-cysteine against tetrachlorobenzoquinone-induced genotoxicity and oxidative stress in HepG2 cells. Food and Chemical Toxicology, 64, 291–297. https://doi.org/10.1016/j.fct.2013.11.036

Dorthu MP, Remy S, Michel-Wolwertz MR, Colleaux L, Breyer D, Beckers MC, Englebert S, Duyckaerts C, Sluse FE and Matagne RF, 1992. Biochemical, genetic and molecular characterization of new respiratory-deficient mutants in Chlamydomonas reinhardtii. Plant Molecular Biology, 18, 759–772.

Doudney CO, White BF and Bruce BJ, 1964. Acriflavine genetic modification of nucleic acid formation, mutation induction and survival in ultraviolet light exposed bacteria. Biochemical and Biophysical Research Communications, 15, 70–75.

Drake JW, 1964. Studies on the induction of mutations in bacteriophage T4 by ultraviolet irradiation and by proflavin. Journal of Cellular Comparative Physiological, 64, 19–32.
Dyes in aquaculture and reference points for action

EFSA CONTAM Panel (EFSA Panel on Contaminants in the Food Chain), 2013. Guidance on methodological principles and scientific methods to be taken into account when establishing Reference Points for Action (RPAs) for non-allowed pharmacologically active substances present in food of animal origin. EFSA Journal 2013;11(4):3195, 24 pp. https://doi.org/10.2903/j.efsa.2013.3195

EFSA Scientific Committee, 2012. Scientific Opinion on Exploring options for providing advice about possible human health risks based on the concept of Threshold of Toxicological Concern (TTC). EFSA Journal 2012;10(7):2750, 103 pp., https://doi.org/10.2903/j.efsa.2012.2750

FAO/WHO (Food and Agriculture Organization of the United Nations/World Health Organization), 2014. Gentian violet. toxicological evaluation of certain veterinary drug residues in food. WHO Food Additives Series, 69, 3–34. Faulkner BM and Arlett CF, 1964. The “minute” cytoplasmic variant of Aspergillus nidulans. Heredity, 19, 63–73. https://doi.org/10.1038/hdy.1964.6

Ferguson LR, 1984. Apparent changes in structure-activity relationships for antimitochondrial effects of 9-anilinoacridines according to Saccharomyces cerevisiae strain and methodology. Mutation Research, 136, 223–231.

Ferguson LR and MacPhee DG, 1983. Frameshift mutagenesis by 9-aminoacridine, ICR191, AMSA and related experimental antitumour acridines in recA+ and recA- strains of Salmonella typhimurium. Mutation Research, 116, 289–296.

Ferguson LR, MacPhee DG and Baguley BC, 1983. Comparative studies of mutagenic, DNA binding and antileukemic properties of 9-anilinoacridine derivatives and related compounds. Chemico-Biological Interactions, 44, 53–62.

Ferguson LR, Pogai H and Turner PM, 1991. Variation in the mutagenic potential of acridines in Salmonella typhimurium, with stage of the culture. Mutation Research - Mutation Research Letters, 262, 227–231. https://doi.org/10.1016/0165-7992(91)90088-L

Firth WJ, Rock SG, Brown BR and Yielding LW, 1981. Azido analogs of acridine: Photoaffinity probes for frameshift mutagenesis in Salmonella typhimurium. Mutation Research, 81, 295–309.

Fujita H, Mizuo A and Hiraga K, 1976. Mutagenicity of dyes in the microbial system. Tokyo-toritsu Eisei Kenkyusho Kenkyu Nempo, 27–2, 153–158.

Gattuso H, Besancenot V, Grandemange S, Marazzi M and Monari A, 2016. From non-covalent binding to irreversible DNA lesions: nile blue and nile red as photosensitizing agents. Science Reports, 6, 10. https://doi.org/10.1038/srep28480

Gendon YZ, 1963. Mutations in polio virus induced by direct action of profilavine on viral RNA [English summary]. Voprusvirusol, 8, 542–547.

Goh CL, 1986. Contact sensitivity to profilavine. International Journal of Dermatology, 25, 449–451.

Hakura A, Mochida H, Tsutsui Y and Yamatsu K, 1994. Mutagenicity and cytotoxicity of naphthoquinones for ames salmonella tester strains. Chemical Research in Toxicology, 7, 559–567. https://doi.org/10.1021/bx00040a012

Harm W, 1973. T4 mediated v gene reactivation of UV irradiated phage T1 and its comparison with host cell reactivation. Mutation Research, 17, 163–176.

Henderson L, Wolfreys A, Fedyk J, Bourner C and Windebank S, 1998. The ability of the Comet assay to discriminate between genotoxins and cytotoxins. Mutation Research, 13, 89–94. https://doi.org/10.1016/S0165-722X(97)00085-9

Hessler AY, 1965. Acidine resistance in bacteriophage T2H as a function of dye penetration measured by mutagenesis and photoactivation. Genetics, 52, 711–722.

Hill RF and Feiner RR, 1964. Further studies of ultraviolet-sensitive mutants of Escherichia coli strain B. Journal of General Microbiology, 35, 105–114.

Hoffman GR, Deschenes SM, Manyin T and Fuchs RP, 1996. Mutagenicity of acridines in a reversion assay based on tetracycline resistance in plasmid pBR322 in Escherichia coli. Mutation Research, 351, 33–43.

Janik-Spiechowicz E, Dzubialtowska E and Wyszynska K, 1997. Mutagenic and genotoxic activity detected by the Ames, micronucleus and SCE tests under the influence of samples of dyes manufactured in Poland. International Journal of Occupational Medicine and Environmental Health, 10, 55–65.

Jensen CS, Menné T and Duus Johansen J, 2006. Systemic contact dermatitis after oral exposure to nickel: a review with a modified meta-analysis. Contact Dermatitis, 54, 79–86. https://doi.org/10.1111/j.0105-1873.2006.00773.x

Jia S, Zhu BZ and Guo LH, 2010. Detection and mechanistic investigation of halogenated benzoquinone induced DNA damage by phototransferchemical DNA sensor. Analytical and Bioanalytical Chemistry, 397, 2395–2400. https://doi.org/10.1007/s00216-010-3796-3

Jia S, Zhu BZ and Guo LH, 2010. Detection and mechanistic investigation of halogenated benzoquinone induced DNA damage by phototransferchemical DNA sensor. Analytical and Bioanalytical Chemistry, 397, 2395–2400. https://doi.org/10.1007/s00216-010-3796-3

Kleijer WJ, Hoeksema JL, Sluiter ML and Bootsm A, 1973. Effects of inhibitors on repair of DNA in normal human and Xeroderma pigmentosum cells after exposure to X rays and ultraviolet irradiation. Mutation Research, 17, 385–394.
Malachov, MacPhee DG, Nagel BA and Podger DM, 1983. Mutagenesis and anti-mutagenesis in Salmonella: in Liu K-h, Wu L-d, Zou X-r, Yang W, Du Q and Su H-m, 2011. Photochemical hydrogen abstraction and electron Lin PH, La DK, Upton PB and Swenberg JA, 2002. Analysis of DNA adducts in rats exposed to pentachlorophenol. Lin PH, Nakamura J, Yamaguchi S, Upton PB, La DK and Swenberg JA, 2001. Oxidative damage and direct adducts in calf thymus DNA induced by the pentachlorophenol metabolites, tetrachlorohydroquinone and tetrachloro-1,4-benzoquinone. Carcinogenesis, 22, 627–634. Lin PH, La DK, Upton PB and Swenberg JA, 2002. Analysis of DNA adducts in rats exposed to pentachlorophenol. Carcinogenesis, 23, 365–369. Liu K-h, Wu L-d, Zou X-r, Yang W, Du Q and Su H-m, 2011. Photochemical hydrogen abstraction and electron transfer reactions of tetrachlorobenzoquinone with pyrimidine nucleobases. Chinese Journal of Chemical Physics, 24, 580–585. https://doi.org/10.1088/1674-0068/24/05/580-585 MacPhee DG, Nagel BA and Podger DM, 1983. Mutagenesis and anti-mutagenesis in Salmonella: influence of etionine and caffeine on yields of mutations influenced by 2-aminopurine and 9-aminooacidine. Mutation Research, 111, 283–293. Malachová K, Pavlicková Z, Novotný C, Svobodová K, Lednícká D and Musilková E, 2006. Reduction in the mutagenicity of synthetic dyes by successive treatment with activated sludge and the ligninolytic fungus, Irpex lacteus. Environmental and Molecular Mutagenesis, 47, 533–540. https://doi.org/10.1002/em.20224 Marcovich H, 1951. The effect of acriflavine on yeast. VIII. Determination of the active component and observations on euflavine. Annales de l’Institut Pasteur, 81, 452–468. Marcovich H, 1953. Relation between the structure of acridines and their activity as inducers of respiratory mutants among yeasts. Annales de l’Institut Pasteur, 85, 199–216. Martin CN, McDermid AC and Garner RC, 1978. Testing of known carcinogens and noncarcinogens for their ability to induce unscheduled DNA synthesis in HeLa cells. Cancer Research, 38, 2621–2627. Masanat YA, Hanby A, Horgan K and Hardie LJ, 2009. DNA damaging effects of the dyes used in sentinel node biopsy: possible implications for clinical practice. Journal of Surgical Research, 154, 234–238. https://doi.org/10.1016/j.jss.2008.07.039 Matsuda S, Matsuda Y, Yanagisawa SY, Ikura M, Ikura T and Matsuda T, 2016. Disruption of DNA damage-response by propyl gallate and 9-aminooacidine. Toxicological Sciences, 151, 224–235. https://doi.org/10.1093/toxsci/kfv039 Mejšel MN and Sokolova TS, 1960. Inherited cytoplasmic changes induced in yeasts by acriflavine and berberine. Doklady Akademii nauk SSSR, 131, 436–439. Meniel V and Waters R, 1999. Spontaneous and photosensitiser-induced DNA single-strand breaks and formamidopyrimidine-DNA glycosylase sensitive sites at nucleotide resolution in the nuclear and mitochondrial DNA of Saccharomyces cerevisiae. Nucleic Acids Research, 27, 822–830. https://doi.org/10.1093/nar/27.3.822 Mitchell IG and Bevan EA, 1973. Definition of the blue mutant phenotype and its genetic basis in Saccharomyces cerevisiae. Genetical Research, 22, 169–179. Mitchell ID, Gilbert PJ, Brice AJ and White DJ, 1981. Somatic eye mutation in Drosophila melanogaster as a short-term test for mutants and carcinogens. Carcinogenesis, 2, 783–786. Mitra RK, Sinha SS, Mai S and Pal SK, 2009. Sequence dependent ultrafast electron transfer of nile blue in oligonucleotides. Journal of Fluorescence, 19, 353–361. https://doi.org/10.1007/s10895-008-0423-1
Dyes in aquaculture and reference points for action

Morgan WF and Crossen PE, 1982. A comparison of induced sister chromatid exchange levels in Chinese hamster ovary cells and cultured human lymphocytes. Environmental Mutagenesis, 4, 65–71. https://doi.org/10.1002/em.2860040109

Morita T and Mifuchi I, 1965. Effect of methylene blue on the action of 4-nitroquinoline N-oxide and acriflavine in inducing respiration-deficient mutants of Saccharomyces cerevisiae. Japanese Journal of Microbiology, 9, 123–129.

Nagai S, 1962. Production of respiration-deficient mutants of yeast by some quinoneimine dyes. Experimental Cell Research, 27, 14–18. https://doi.org/10.1016/0014-4827(62)90038-1

Nagai S, 1963. Methylene blue and toluidine blue interfering with the production of respiration-deficient mutants in yeast by acriflavine. Experimental Cell Research, 29, 82–85. https://doi.org/10.1016/0014-4827(63)90360-4

Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (CAS: Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.

NTP (National Toxicology Program), 1989. NTP toxicology and carcinogenesis studies of rhodamine 6g (c.I. Basic Nestmann ER, Douglas GR and Matula TI, 1979. Mutagenic activity of rhodamine dyes and their impurities as detected by mutation induction in Salmonella and DNA damage in Chinese hamster ovary cells. Cancer Research, 39, 4412–4417.
Sun TS and Stahr HM, 1993. Evaluation and application of a bioluminescent bacterial genotoxicity test. Journal of AOAC International, 76, 893–898.

Sushil K and Natarajan AT, 1965. Photodynamic action and post-irradiation modifying effects of methylene blue and acridine orange in barley and *Vicia faba*. Mutation Research, 2, 11–21.

Sychyova LP, Sheremetyeva SM, Krivtsova YK, Zhurkov VS and Golovach YN, 2007. Assessment of cytogenetic activity of methylene blue and products of its photo decomposition in a polyorganic micronuclear assay on rats. Toksiologicheski Vestnik, 18–21.

Takahashi T, 1972. Abnormal mitosis by some $\mu$-mutagens in *Saccharomyces cerevisiae*. Bulletin of Brewing Science, 18, 37–48.

Vaidyanathan VG, Villalta PW and Sturla SJ, 2007. Nucleobase-dependent reactivity of a quinone metabolite of pentachlorophenol. Chemical Research in Toxicology, 20, 913–919. https://doi.org/10.1021/tx060359d

Wagner SJ, Cifone MA, Murli H, Dodd RX and Myhr B, 1995. Mammalian genotoxicity assessment of methylene blue in plasma: implications for virus inactivation. Transfusion, 35, 407–413.

Waidyanatha S, Lin PH and Rappaport SM, 1996. Characterization of chlorinated adducts of hemoglobin and albumin following administration of pentachlorophenol to rats. Chemical Research in Toxicology, 9, 647–653. https://doi.org/10.1021/tx950172n

Waidyanatha S, McDonal TA, Lin PH and Rappaport SM, 1994. Measurement of hemoglobin and albumin adducts of tetrachlorobenzoquinone. Chemical Research in Toxicology, 7, 463–468.

Webb RB and Hass BS, 1984. Biological effects of dyes on bacteria. VI. Mutation induction by acridine orange and methylene blue in the dark with special reference to *Escherichia coli* WP6 (polA1). Mutation Research, 137, 1–6.

Webb RB, Hass BS and Kubitschek HE, 1979. Photodynamic effects of dyes on bacteria. II. Genetic effects of broad spectrum visible light in the presence of acridine dyes and methylene blue in chemostat cultures of *Escherichia coli*. Mutation Research, 59, 1–13.

Wild DG and Hinshelwood C, 1956. The response of yeast cells to the action of inhibitory substances. I. Sodium azide. II. Crystal violet. III. Janus black and some other agents. Proceedings of the Royal Society of London. Series B, 156, 14–41.

Witkin EM, 1947. Mutations in *Escherichia coli* induced by chemical agents. Cold Spring Harbor Symposia on Quantitative Biology, 12, 256–269. https://doi.org/10.1101/SQB.1947.012.01.027

Witkin EM, 1961. Modification of mutagenesis initiated by ultraviolet light through posttreatment of bacteria with basic dyes. Journal of Cellular Physiology, 58, 135–144. https://doi.org/10.1002/jcp.103058014

Xamena N, Creus A and Marcos R, 1984. Mutagenic activity of some intercalating compounds in the *Drosophila zeste* somatic eye mutation test. Mutation Research - Genetic Toxicology and Environmental Mutagenesis, 138, 169–173. https://doi.org/10.1016/0165-1218(84)90040-5

Young PR, Ma RI, Marfrey P and Kallenbach NR, 1981. Frameshift mutagenesis of 9-aminoacridine derivatives in *Salmonella typhimurium*. Mutation Research, 90, 1–10.

Younis SEA, Ali AMM and Hussien MY, 1975. The specificity of acriflavine in inducing mutations in *Bacillus subtilis* and *Escherichia coli* row. Bulletin of the Faculty of Science Assiut University, 4, 1–10.

Zhang H, Xu Y, Kamendulis LM and Klaunig JE, 2000. Morphological transformation by 8-hydroxy-2'-deoxyguanosine in Syrian hamster embryo (SHE) cells. Toxicological Sciences, 56, 303–312.

Zhao GC, Zhu JJ, Chen HY, Wang XM and Lu ZH, 2002. Spectroscopic and spectroelectrochemical studies of interaction of Nile Blue with DNA. Chinese Journal of Chemistry, 20, 57–62.

Zhu B-Z and Shan G-Q, 2009. Potential mechanism for pentachlorophenol-induced carcinogenicity: a novel mechanism for metal-independent production of hydroxyl radicals. Chemical Research in Toxicology, 22, 969–977. https://doi.org/10.1021/tx900300v

Zhu B-Z, Zhu J-G, Fan R-M and Mao L, 2011. Metal-independent pathways of chlorinated phenol/quinone toxicity. In: Fishbein JC (ed.). Advances in Molecular Toxicology. Volume 5. Elsevier B.V., Amsterdam, the Netherlands. pp. 1–43.

Zimina TA and Pavlenko VV, 1990. Toxic and mutagenic effects of some dyes. Genetika (Moscow), 26, 2246–2249.

**Abbreviations**

- **ACD**: allergic contact dermatitis
- **Bw**: body weight
- **CVMP**: Committee for Veterinary Medicinal Products
- **DPRA**: Direct Peptide Reactivity Assay
- **EC**: Enzyme Commission
- **ECHA**: European Chemicals Agency
- **ELISA**: enzyme-linked immunosorbent assay
- **EMA**: European Medicines Agency
- **HepG2**: human hepatoma cells
- **IgE**: immunoglobulin E
- **IUPAC**: International Union of Pure and Applied Chemistry
| Abbreviation | Description |
|--------------|-------------|
| JECFA | Joint FAO/WHO Expert Committee on Food Additives |
| MRL | maximum residue limit |
| Ni | nickel |
| OECD | Organisation for Economic Co-operation and Development |
| PCP | pentachlorophenol |
| (Q)SAR | quantitative structure–activity relationship |
| RALLOQ | reasonably achievable lowest limit of quantification |
| RPA | reference point for action |
| SCCNFP | Scientific Committee on cosmetic products and non-food products intended for consumers |
| SCD | systemic contact dermatitis |
| TBLOQ | toxicologically based limit of quantification |
| TSV | toxicological screening value |
| TTC | threshold of toxicological concern |
| UV | ultraviolet |
| VMP | veterinary medicinal product |
Appendix A – Literature search

A.1. Identification and selection of evidence related to allergy

1) WEB OF SCIENCE
   
   TOPIC: (substance OR synonym) AND TOPIC: (allergy or dermatitis); Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years

2) PUBMED
   
   (substance OR synonym) AND (allergy or dermatitis)

A.2. Identification and selection of evidence related to blood dyscrasias

1) WEB OF SCIENCE
   
   TOPIC: (substance OR synonym) AND TOPIC: (anaemia or ‘blood dyscrasias’); Indexes=SCI-EXPANDED, SSCI, A&HCI, CPCI-S, CPCI-SSH, BKCI-S, BKCI-SSH, ESCI, CCR-EXPANDED, IC Timespan=All years

2) PUBMED
   
   (substance OR synonym) AND (anaemia or ‘blood dyscrasias’)

A.3. Identification and selection of evidence related to genotoxicity

A.3.1. Nile blue and trypan red

1) EMBASE
   
   (substance OR synonym) AND (‘toxicity’/exp OR ‘toxic substance’/exp OR ‘toxicity assay’/exp OR ‘toxicity testing’/exp OR ‘mutagenesis’/exp OR ‘mutagen testing’/exp OR ‘carcinogenesis’/exp OR ‘carcinogenic activity’/exp OR ‘carcinogen dna interaction’/exp OR ‘dna adduct’/exp OR ‘carcinogen testing’/exp OR ‘genetic damage’/exp OR ‘chromosome aberration’/exp OR ‘chromatid aberration’/exp OR toxic*:ab,ti OR genotox*:ab,ti OR carcinogen*:ab,ti OR mutagen*:ab,ti OR teratogen*:ab,ti OR aneugen*:ab,ti OR clastogen*:ab,ti OR promutagen*:ab,ti OR tum*rigen*:ab,ti OR ‘dna adduct’*:ab,ti OR chromosom*:ab,ti OR chromatid*:ab,ti OR ‘dna damage’:ab,ti)

2) PUBMED
   
   (substance OR synonym) AND (genotox* OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen* OR chromosom* OR cancer* OR carcino* OR tumor* OR tumour* OR rat OR rats OR mouse OR mice)

3) SCIFINDER
   
   • toxicity of CAS number
   • mutagenicity of CAS number
   • genotoxicity of CAS number
   • carcinogenity of CAS number

4) WEB OF SCIENCE
   
   TOPIC: (substance OR synonym) AND TOPIC: (genotox* OR muta* OR DNA OR damage OR repair OR clastogen* OR aneugen* OR chromosom* OR cancer* OR carcino* OR tumor* OR tumour* OR rat OR rats OR mouse OR mice)

A.3.2. Other substances

1) EMBASE
   
   (substance OR synonym) AND (‘genotoxicity’/exp OR ‘mutagenic agent’/exp OR ‘genetic damage’/exp OR ‘dna adduct’/exp OR ‘dna binding’/exp OR ‘dna repair’/exp OR ‘chromosome aberration’/exp OR ‘chromatid aberration’/exp OR ‘mutation’/exp OR ‘genotoxicity assay’/exp OR ‘mutagen testing’/exp OR genotox*:ab,ti OR mutation*:ab,ti OR aneugen*:ab,ti OR clastogen*:ab,ti OR (dna
OR chromosom* OR chromatid* OR genetic*) NEAR/3 (damage OR alteration* OR break* OR mutation* OR aberration* OR interaction* OR adduct* OR repair)) AND ([article]/lim OR [article in press]/lim OR [review]/lim)

2) **PUBMED**

(substance OR synonym) AND ("Mutagens"[Mesh] OR "DNA Damage"[Mesh] OR "DNA repair"[Mesh] OR "Mutagenesis"[Mesh] OR "Mutation"[Mesh] OR "Mutagenicity Tests"[Mesh] OR genotox*[tiab] OR mutation*[tiab] mutagen*[tiab] OR aneugen*[tiab] OR clastogen*[tiab] OR ((DNA [tiab] OR chromosom*[tiab] OR chromatid*[tiab] OR genetic*[tiab]) AND (damage[tia] OR alteration* [tiab] OR break*[tiab] OR mutation*[tiab] OR aberration*[tiab] OR interaction*[tiab] OR adduct*[tiab] OR repair[tiab])))

3) **SCIFINDER**

Mutagenicity or genotoxicity of CAS number

4) **WEB OF SCIENCE**

TOPIC: (substance OR synonym) AND TOPIC: (genotox* OR mutation* OR mutagen* OR aneugen* OR clatogen* OR (DNA OR chromosom* OR chromatid* OR genetic*)) NEAR/3 (damage OR alteration* OR break* OR mutation* OR aberration* OR interaction* OR adduct* OR repair)); Refined by: DOCUMENT TYPES: (ARTICLE OR REVIEW); Timespan: All years; Search language=Auto